

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

**COMIRNATY®**

COVID-19 mRNA vaccine

Suspension for Intramuscular Injection

**Single Dose Vial**

30 mcg/0.3 mL

10 mcg/0.3 mL

**Multiple Dose Vial**

30 mcg/0.3 mL (6 doses/vial)

10 mcg/0.3 mL (6 doses/vial)

3 mcg/0.3 mL (3 doses/vial after dilution)

**Single Dose Prefilled Syringe**

30 mcg/0.3 mL

Active Immunizing Agent

Omicron KP.2 variant

ATC Classification J07BN01

COMIRNATY® [COVID-19 mRNA Vaccine] vaccine is indicated for:

- Active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.

COMIRNATY® [COVID-19 mRNA Vaccine] vaccine has been issued marketing authorization with Terms and Conditions that need to be met by the Market Authorization Holder to ascertain the continued quality, safety and effectiveness of the vaccine.

Patients should be advised of the nature of the authorization. For further information for COMIRNATY® [COVID-19 mRNA Vaccine] please refer to Health Canada's [COVID-19 vaccines and treatments portal](#).

BioNTech Manufacturing GmbH  
An der Goldgrube 12  
Mainz, Rhineland-Palatinate, Germany 55131

**Imported and distributed by:**  
Pfizer Canada ULC  
17,300 Trans-Canada Highway  
Kirkland, Quebec, Canada H9J 2M5

Date of Initial Authorization:  
September 28, 2023

Date of Revision:  
October 25, 2024

Submission Control Number: 284411

RECENT MAJOR LABEL CHANGES

4 Dosage and Administration	09/2024
7 Warnings and Precautions - Cardiovascular	10/2024

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

**RECENT MAJOR LABEL CHANGES ..... 2**

**TABLE OF CONTENTS ..... 2**

**PART I: HEALTH PROFESSIONAL INFORMATION ..... 6**

**1 INDICATIONS..... 6**

1.1 Pediatrics..... 6

1.2 Geriatrics ..... 6

**2 CONTRAINDICATIONS..... 6**

**3 SERIOUS WARNINGS AND PRECAUTIONS..... 6**

**4 DOSAGE AND ADMINISTRATION..... 6**

4.1 Dosing Considerations ..... 6

4.2 Recommended Dose and Dosage Adjustment ..... 7

4.2.1 Vaccination Schedule for Individuals 12 Years of Age and Older ..... 7

4.2.2 Vaccination Schedule for Individuals Aged 5 Years Through 11 Years ..... 7

4.2.3 Vaccination Schedule for Individuals Aged 6 Months Through 4 Years ..... 7

4.3 Reconstitution ..... 8

4.3.1 Vials with Yellow Cap/Label Border (for Age 6 Months Through 4 Years) ..... 8

4.4 Administration ..... 9

4.4.1 Preparation for Administration ..... 9

4.4.1.1 Vials with Gray Cap/Label Border (for 12 Years and Older) and Vials with Blue Cap/Label Border (for Age 5 Through 11 Years)..... 9

4.4.1.2 Vials with Yellow Cap/Label Border (for Age 6 Months Through 4 Years) ..... 10

4.4.1.3 Prefilled Syringe (For 12 Years and Older)..... 11

4.4.2 Administration..... 11

**5 OVERDOSAGE..... 12**

**6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ..... 12**

<b>7</b>	<b>WARNINGS AND PRECAUTIONS.....</b>	<b>13</b>
7.1	Special Populations .....	15
7.1.1	Pregnant Women .....	15
7.1.2	Breast-feeding .....	15
7.1.3	Pediatrics .....	15
7.1.4	Geriatrics .....	15
<b>8</b>	<b>ADVERSE REACTIONS .....</b>	<b>15</b>
8.1	Adverse Reaction Overview .....	15
8.1.1	COMIRNATY Original & Omicron BA.4/BA.5 (15 mcg/15 mcg).....	15
8.1.2	COMIRNATY Original & Omicron BA.4/BA.5 (5 mcg/5 mcg).....	16
8.1.3	COMIRNATY Original & Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg).....	16
8.1.4	COMIRNATY (Original: 30 mcg) .....	17
8.1.5	COMIRNATY (Original: 10 mcg) .....	18
8.1.6	COMIRNATY (Original: 3 mcg) .....	19
8.2	Clinical Trial Adverse Reactions .....	20
8.2.1	COMIRNATY Original & Omicron BA.4/BA.5 (15 mcg/15 mcg).....	20
8.2.2	COMIRNATY Original & Omicron BA.4/BA.5 (5 mcg/5 mcg).....	22
8.2.3	COMIRNATY Original & Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg).....	24
8.2.4	COMIRNATY (Original: 30 mcg) .....	28
8.2.5	COMIRNATY (Original: 10 mcg) .....	38
8.2.6	COMIRNATY (Original: 3 mcg) .....	43
8.5	Post-Market Adverse Reactions.....	47
<b>9</b>	<b>DRUG INTERACTIONS .....</b>	<b>47</b>
<b>10</b>	<b>CLINICAL PHARMACOLOGY.....</b>	<b>47</b>
10.1	Mechanism of Action .....	47
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL.....</b>	<b>48</b>
<b>12</b>	<b>SPECIAL HANDLING INSTRUCTIONS.....</b>	<b>49</b>
	<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>50</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION .....</b>	<b>50</b>
<b>14</b>	<b>CLINICAL TRIALS .....</b>	<b>51</b>
14.1	Trial Design and Study Demographics .....	51

14.1.1	COMIRNATY Original & Omicron BA.4/BA.5 (15/15mcg) .....	51
14.1.2	COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg) .....	51
14.1.3	COMIRNATY (Original: 30 mcg) .....	51
14.1.4	COMIRNATY (Original: 10 mcg) .....	53
14.1.5	COMIRNATY (Original: 3 mcg) .....	55
14.2	Study Results .....	55
14.2.1	COMIRNATY Original & Omicron BA.4/BA.5 (15/15mcg) .....	55
14.2.1.1	Immunogenicity in Participants 12 Years of Age and Older – After Second Booster Dose (Fourth Dose) .....	55
14.2.2	COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg) .....	59
14.2.2.1	Immunogenicity in Participants 6 Months Through <5 Years of Age – After Booster (Fourth Dose) .....	59
14.2.3	COMIRNATY (Original: 30 mcg) .....	60
14.2.3.1	Efficacy and Immunogenicity in Participants 16 Years of Age and Older .....	60
14.2.3.1.1	Efficacy in Participants 16 Years of Age and Older – After Two Doses....	60
14.2.3.1.2	Efficacy and Immunogenicity in Participants 16 Years of Age and Older – After Booster Dose.....	62
14.2.3.2	Efficacy and Immunogenicity in Adolescents 12 to 15 Years of Age .....	65
14.2.3.2.1	Efficacy and Immunogenicity in Adolescents 12 to 15 Years of Age – After Two Doses.....	65
14.2.3.3	Coadministration of COMIRNATY with Influenza Vaccine .....	67
14.2.4	COMIRNATY (Original: 10 mcg) .....	67
14.2.4.1	Efficacy and Immunogenicity in Children 5 Years Through <12 Years of Age. ....	67
14.2.4.1.1	Efficacy and Immunogenicity in Children 5 Years Through <12 Years of Age – After Two Doses.....	67
14.2.4.2	Immunogenicity in Children 5 Years Through <12 Years of Age – After Booster Dose .....	69
14.2.5	COMIRNATY (Original: 3 mcg) .....	70
14.2.5.1	Immunogenicity in Children 6 Months Through <5 Years of Age .....	70
14.2.5.1.1	Immunogenicity in Children 6 Months Through <5 Years of Age – After a 3-Dose Primary Series .....	70
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>74</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>74</b>

**PATIENT MEDICATION INFORMATION ..... 76**

## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

COMIRNATY (COVID-19 mRNA Vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) in individuals 6 months of age and older (see [4.2 Recommended Dose and Dosage Adjustment](#)).

The safety and effectiveness of COMIRNATY for individuals 6 months of age and older are inferred from studies which evaluated the primary series and booster vaccination with COMIRNATY (Original)<sup>1</sup> and supported by studies which evaluated a booster dose of COMIRNATY Original & Omicron BA.4/BA.5 in individuals 6 months of age and older.

#### 1.1 Pediatrics

The safety and efficacy of COMIRNATY in children under 6 months of age have not yet been established.

#### 1.2 Geriatrics

Clinical studies of COMIRNATY (Original) and COMIRNATY Original & Omicron BA.4/BA.5 included participants 65 years of age and older and their data contribute to the overall assessment of the safety and efficacy of COMIRNATY (see [8 ADVERSE REACTIONS](#) and [14 CLINICAL TRIALS](#)).

### 2 CONTRAINDICATIONS

COMIRNATY is contraindicated in individuals who are hypersensitive to the active substance or to any ingredient in the formulation. For a complete listing see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).

### 3 SERIOUS WARNINGS AND PRECAUTIONS

At the time of authorization, there are no known serious warnings or precautions associated with this product.

### 4 DOSAGE AND ADMINISTRATION

#### 4.1 Dosing Considerations

COMIRNATY is a suspension for intramuscular injection.

The storage, preparation and administration information differ depending on which presentation of the vaccine is considered. **Careful attention should be paid to the vial cap and label border colour and information on the label, and the appropriate corresponding instructions for each presentation must be followed under the subsections below.**

---

<sup>1</sup> COMIRNATY (Original) refers to the Original monovalent vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu 1 strain (wildtype).

Age Range of Recipient and Strength	Presentation	Vial Cap and Label Colour	Dilution required	Dose Volume
12 years and older 30 mcg per dose	Multiple dose vial: six 0.3 mL doses per vial	Dark gray	No	0.3 mL
	Single dose vial: one 0.3 mL dose per vial	Light gray	No	0.3 mL
	Single dose prefilled syringe: one 0.3 mL dose per syringe	--	No	0.3 mL
5 through 11 years 10 mcg per dose	Multiple dose vial: six 0.3 mL doses per vial	Dark blue	No	0.3 mL
	Single dose vial: one 0.3 mL dose per vial	Light blue	No	0.3 mL
6 months through 4 years 3 mcg per dose	Multiple dose vial: three 0.3 mL doses per vial after dilution	Yellow	Yes	0.3 mL

## 4.2 Recommended Dose and Dosage Adjustment

### 4.2.1 Vaccination Schedule for Individuals 12 Years of Age and Older

COMIRNATY is administered intramuscularly as a single dose of 0.3 mL, regardless of prior COVID-19 vaccination status.

For individuals who have previously been vaccinated with a COVID-19 vaccine, COMIRNATY should be administered at least 3 to 6 months after the most recent dose of a COVID-19 vaccine.

### 4.2.2 Vaccination Schedule for Individuals Aged 5 Years Through 11 Years

COMIRNATY is administered intramuscularly as a single dose of 0.3 mL, regardless of prior COVID-19 vaccination status.

For individuals who have previously been vaccinated with a COVID-19 vaccine, COMIRNATY should be administered at least 6 months after the most recent dose of a COVID-19 vaccine.

### 4.2.3 Vaccination Schedule for Individuals Aged 6 Months Through 4 Years

#### Without history of completion of a COVID-19 primary course

COMIRNATY is administered intramuscularly as a three-dose course (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose, followed by a third dose administered at least 8 weeks after the second dose.

If an infant or child starts a primary vaccination course with COMIRNATY XBB.1.5, they may complete the three-dose course with COMIRNATY.

The interchangeability of COMIRNATY with COVID-19 vaccines from other manufacturers to complete the three-dose course has not been established. Individuals who have received a dose of COMIRNATY should receive COMIRNATY to complete the three-dose course.

*With history of completion of a COVID-19 primary course*

COMIRNATY is administered intramuscularly as a single dose of 0.3 mL for infants and children 6 months through 4 years.

For individuals who have previously been vaccinated with a COVID-19 vaccine, COMIRNATY should be administered at least 6 months after the most recent dose of a COVID-19 vaccine.

**4.3 Reconstitution**

Only the multiple dose vial with yellow cap/label border (for age 6 months through 4 years) is diluted before use. For handling and preparation of other presentations prior to administration, please see [4.4.1 Preparation for Administration](#).

**4.3.1 Vials with Yellow Cap/Label Border (for Age 6 Months Through 4 Years)**

Verify that the vial has a yellow plastic cap and a label with a yellow border.

COMIRNATY multiple dose vials with yellow cap and yellow label border (for age 6 months through 4 years) are supplied as a frozen suspension that does not contain preservative. Each vial must be thawed and diluted prior to administration.

***Thawing Prior to Dilution***

- Thaw multiple dose vial(s) before use either by:
  - Allowing vial(s) to thaw in the refrigerator [2°C to 8°C (35°F to 46°F)]. A carton of 10 vials may take up to 2 hours to thaw, and thawed vials can be stored in the refrigerator for up to 10 weeks prior to use within the expiry date printed on the carton. Upon moving vials to 2°C to 8°C storage, update the expiry date on the carton.
  - Allowing vial(s) to sit at room temperature [up to 25°C (77°F)] for 30 minutes.
  - Thawed vials may be stored at room temperature [up to 25°C (77°F)] for up to 12 hours prior to dilution.
- Before dilution, allow the thawed vial to come to room temperature.
- When at room temperature, mix by inverting vaccine vial gently 10 times.
- Do not shake.
- Inspect the liquid in the vial prior to dilution. The liquid is a clear to slightly opalescent suspension and may contain white to off-white opaque amorphous particles.
- Do not use if liquid is discoloured or if other particles are observed.

***Dilution***

- Obtain sterile 0.9% Sodium Chloride Injection, USP. Use only this as the diluent. This diluent is not packaged with the vaccine and must be sourced separately. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.
- Using aseptic technique, withdraw 1.1 mL of diluent into a transfer syringe (using 21-gauge or narrower needle).
- Cleanse the vaccine vial stopper with a single-use antiseptic swab.
- Add 1.1 mL of 0.9% Sodium Chloride Injection, USP into the vaccine vial.



- Equalize vial pressure before removing the needle from the vial by withdrawing 1.1 mL air into the empty diluent syringe.
- Gently invert the vial 10 times to mix.
- Do not shake.
- Inspect the vaccine in the vial.
- The vaccine will be a clear to slightly opalescent suspension with no particulates visible. Do not use if vaccine is discoloured or contains particulate matter.
- After dilution, record the discard time on vial label. Store between 2°C to 25°C (35°F to 77°F) and use within 12 hours. Discard any unused vaccine 12 hours after dilution.
- Do not freeze or shake the diluted vaccine. If refrigerated, allow the diluted vaccine to come to room temperature prior to use.

## 4.4 Administration

### 4.4.1 Preparation for Administration

#### 4.4.1.1 Vials with Gray Cap/Label Border (for 12 Years and Older) and Vials with Blue Cap/Label Border (for Age 5 Through 11 Years)

COMIRNATY single dose or multiple dose vials with a gray cap/label border (for 12 years and older) and with a blue cap/label border (for age 5 through 11 years) are supplied as a frozen suspension that does not contain preservative. Each vial must be thawed prior to administration. **DO NOT DILUTE prior to use.** Instructions on thawing and dose preparation of the vaccine prior to administration are provided below.

#### ***Vial and Dose Verification***

- Verify that:
  - the vial has a **gray cap and a label with a gray border** for use in 12 years and older.
  - the vial has a **blue cap and a label with a blue border** for use in age 5 through 11 years.
  - the vial is a single dose vial (containing 1 dose) or a multiple dose vial (containing 6 doses) by checking the label and follow the applicable handling instructions below.

#### ***Thawing Prior to Use***

- Thaw single dose or multiple dose vial(s) before use either by:
  - Allowing vial(s) to thaw in the refrigerator [2°C to 8°C (35°F to 46°F)].
    - Single dose vials: A 10 vial pack of single dose vials may take 2 hours to thaw.
    - Multiple dose vials: A 10 vial pack of multiple dose vials may take 6 hours to thaw.
  - Allowing vial(s) to sit at room temperature [up to 25°C (77°F)] for 30 minutes.
- Thawed vials can be stored in the refrigerator [2°C to 8°C (35°F to 46°F)] for up to 10 weeks prior to use within the expiry date printed on the carton. Upon moving vials to 2°C to 8 °C storage, update the expiry date on the carton.
- Thawed vials may be stored at room temperature [up to 25°C (77°F)] for up to 12 hours prior to use.

#### ***Preparation of Individual 0.3 mL Doses***

- Before use, mix by inverting vaccine vial gently 10 times.

- Do not shake.
- Prior to mixing:
  - Gray cap vials: The thawed vaccine is a white to off-white suspension and may contain white to off-white opaque amorphous particles.
  - Blue cap vials: The thawed vaccine is a clear to slightly opalescent suspension and may contain white to off-white opaque amorphous particles.
- After mixing:
  - Gray cap vials: The vaccine should appear as a white to off-white suspension with no visible particles.
  - Blue cap vials: The vaccine should appear as a clear to slightly opalescent suspension with no visible particles.
- Do not use if liquid is discoloured or if particles are observed after mixing.

#### *Single dose vials*

- Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab, and withdraw a single 0.3 mL dose.
- Discard vial and any excess volume. Do not pool excess vaccine from multiple vials.

#### *Multiple dose vials*

- Multiple dose vials contain 6 doses of 0.3 mL each.
  - Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. In order to ensure consistent withdrawal of 6 doses of 0.3 mL, it is important to adhere to minimizing volume loss during dose extraction.
- Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab, and withdraw a single 0.3 mL dose preferentially using a low dead-volume syringe and/or needle.
- Administer immediately and no later than 12 hours after first puncture.
- After first puncture, record the discard time on the vial label. Store between 2°C to 25°C (35°F to 77°F) and use within 12 hours.
- Each dose must contain 0.3 mL of vaccine.
- If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume. Do not pool excess vaccine from multiple vials.
- Discard any unused vaccine 12 hours after first puncture.

#### **4.4.1.2 Vials with Yellow Cap/Label Border (for Age 6 Months Through 4 Years)**

COMIRNATY multiple dose vials with a yellow cap and yellow label border (for age 6 months through 4 years) **MUST BE DILUTED** prior to administration. Please see [4.3 Reconstitution](#) for instructions on thawing and dilution.

**Preparation of Individual 0.3 mL Doses**

- After dilution, multiple dose vials contain 3 doses of 0.3 mL each. Standard syringes and needles can be used.
- Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab, and withdraw a single 0.3 mL dose.
- Administer immediately and no later than 12 hours after dilution.
- Each dose must contain 0.3 mL of vaccine.
- If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume. Do not pool excess vaccine from multiple vials.
- Store between 2°C to 25°C (35°F to 77°F). Discard any unused vaccine 12 hours after dilution.

**4.4.1.3 Prefilled Syringe (For 12 Years and Older)**

- Prior to use, the prefilled syringes can be stored for up to 12 hours at temperatures between 8 °C to 25 °C and can be handled in room light conditions. If prefilled syringe has been frozen, discard.
- Do not shake.
- Remove tip cap by slowly turning the cap counterclockwise while holding the luer lock.
- Attach a needle appropriate for intramuscular injection and administer the entire volume to deliver a 0.3 mL dose.

**4.4.2 Administration**

Administer a single 0.3 mL dose of COMIRNATY intramuscularly.

- In individuals 6 months to less than 12 months of age: administer COMIRNATY in the anterolateral aspect of the thigh.
- In individuals 1 year through 4 years of age: administer COMIRNATY in the anterolateral aspect of the thigh or the deltoid muscle.
- In individuals 5 years of age and older: administer COMIRNATY in the deltoid muscle.

Do not inject the vaccine intravascularly, subcutaneously or intradermally.

Visually inspect each dose in the dosing syringe prior to administration.

- Vials with gray cap/label borders and prefilled syringes: The vaccine will be an off-white suspension.
- Vials with blue cap/label borders and yellow caps/label borders: The vaccine will be a clear to slightly opalescent suspension.

During the visual inspection:

- Verify the final dosing volume of 0.3 mL.
- Confirm there are no particulates and that no discolouration is observed.
- Do not administer if vaccine is discoloured or contains particulate matter.

## 5 OVERDOSAGE

In the event of suspected overdose, monitoring of vital functions and symptomatic treatment is recommended. Contact your regional poison control centre.

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

To help ensure the traceability of vaccines for patient immunization record-keeping as well as safety monitoring, health professionals should record the time and date of administration, quantity of administered dose (if applicable), anatomical site and route of administration, brand name and generic name of the vaccine, the product lot number and expiry date.

**Table 1: Dosage Forms, Strengths, Composition and Packaging**

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Intramuscular injection	<p>Suspension</p> <p><sup>1</sup>mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2</p> <p><b>Single Dose Vial</b></p> <p>30 mcg/0.3 mL</p> <p>10 mcg/0.3 mL</p> <p><b>Multiple Dose Vial</b></p> <p>30 mcg/0.3 mL (6<sup>†</sup> doses/vial)</p> <p>10 mcg/0.3 mL (6<sup>†</sup> doses/vial)</p> <p>3 mcg/0.3 mL (3 doses/vial after dilution)</p> <p><b>Single Dose Prefilled Syringe</b></p> <p>30 mcg/0.3 mL</p>	<ul style="list-style-type: none"> <li>• ALC-0315 = ((4-hydroxybutyl)azanediyl)bis (hexane-6,1-diyl)bis(2-hexyldecanoate)</li> <li>• ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide</li> <li>• cholesterol</li> <li>• DSPC = 1,2-distearoyl-sn-glycero-3-phosphocholine</li> <li>• sodium chloride<sup>2</sup></li> <li>• sucrose</li> <li>• tromethamine</li> <li>• tromethamine hydrochloride</li> <li>• water for injection</li> </ul>

<sup>1</sup> mRNA encoding SARS-CoV-2 spike protein, 5' [m<sub>2</sub><sup>7,3'-O</sup>Gppp(m<sub>1</sub><sup>2'-O</sup>)ApG] cap, 110-nucleotide 3' poly(A) tail with a 10-nucleotide linker sequence

<sup>2</sup> present only in the 3 mcg/0.3 mL (yellow cap vial) presentation following dilution with 0.9% Sodium Chloride Injection USP

COMIRNATY is supplied as a frozen suspension in single dose or multiple dose vials or as a refrigerated suspension (DO NOT FREEZE) in single dose prefilled syringes. Each dose contains nucleoside modified messenger RNA (modRNA) encoding the viral spike (S) protein of SARS-CoV-2 and the non-medicinal ingredients listed in Table 1.

The mRNA encoding spike protein is derived from Omicron variant KP.2.

COMIRNATY is supplied in the following presentations (not all may be marketed).

<sup>†</sup> Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract a 6<sup>th</sup> dose from a single vial.

For 12 Years of Age and Older:

- *Single Dose Vial with Light Gray Cap and Light Gray Label Border (DO NOT DILUTE):* 1 dose of 0.3 mL (30 micrograms mRNA/0.3 mL).
- *Multiple Dose Vial with Dark Gray Cap and Dark Gray Label Border (DO NOT DILUTE):* 6 doses of 0.3 mL, (30 micrograms mRNA/0.3 mL)
- *Single Dose Prefilled Syringe:* 1 dose of 0.3 mL (30 micrograms mRNA/0.3 mL)

For Age 5 Years Through 11 Years:

- *Single Dose Vial with Light Blue Cap and Light Blue Label Border (DO NOT DILUTE):* 1 dose of 0.3 mL (10 micrograms mRNA/0.3 mL).
- *Multiple Dose Vial with Dark Blue Cap and Dark Blue Label Border (DO NOT DILUTE):* 6 doses of 0.3 mL (10 micrograms mRNA/0.3 mL).

For Age 6 Months Through 4 Years:

- *Multiple Dose Vial with Yellow Cap and Yellow Label Border (DILUTE PRIOR TO USE):* 3 doses of 0.3 mL after dilution (3 micrograms mRNA/0.3 mL)

COMIRNATY does not contain preservative.

The vial stoppers are not made with natural rubber latex.

The prefilled syringe tip cap and plunger stopper are not made with natural rubber latex.

COMIRNATY is supplied as:

- Cartons of 10 single dose vials
- Cartons of 10 multiple dose vials
- Cartons of 10 single dose prefilled syringes

## 7 WARNINGS AND PRECAUTIONS

### General

The administration of COMIRNATY should be postponed in individuals suffering from acute severe febrile illness.

Fainting may occur in association with administration of injectable vaccines. Individuals should be advised to bring symptoms (e.g., dizziness, increases in heart rate, feeling short of breath, tingling sensations or sweating) to the attention of the vaccination provider for evaluation. Procedures should be in place to avoid injury from fainting.

As with any vaccine, vaccination with COMIRNATY may not protect all recipients.

### Acute Allergic Reactions

Anaphylaxis has been reported. As with all vaccines, training for immunizers, appropriate medical treatment and supervision after immunization should always be readily available in case of a rare anaphylactic event following the administration of this vaccine.

Vaccine recipients should be kept under observation for at least 15 minutes after immunization; 30

minutes is a preferred interval when there is a specific concern about a possible vaccine reaction.

COMIRNATY should not be given to those who have experienced anaphylaxis after a prior dose of any COMIRNATY vaccine.

## **Cardiovascular**

### Myocarditis and Pericarditis

Very rare cases of myocarditis and/or pericarditis following vaccination with COMIRNATY have been reported during post-authorization use. These cases occurred more commonly after the second dose or first booster dose in adolescent and young adult males. Typically, the onset of symptoms has been within a few days following receipt of COMIRNATY. Based on accumulating data, the reporting rates of myocarditis and pericarditis after COMIRNATY primary series in children ages 5 through <12 years are lower than in ages 12 through 17 years.

Available short-term follow-up data suggest that the symptoms resolve in most individuals, but information on long-term sequelae is lacking. Some reported cases required intensive care support. Although causality has not been established, fatal events have been very rarely reported. Post-authorization data indicate that myocarditis and pericarditis following vaccination are more commonly of shorter duration and less severe than infectious myocarditis or pericarditis. The decision to administer COMIRNATY to an individual with a history of myocarditis or pericarditis should take into account the individual's clinical circumstances.

Healthcare professionals are advised to consider the possibility of myocarditis and/or pericarditis in their differential diagnosis if individuals present with chest pain, shortness of breath, palpitations or other signs and symptoms of myocarditis and/or pericarditis following immunization with a COVID-19 vaccine. This could allow for early diagnosis and treatment. Cardiology consultation for management and follow up should be considered.

## **Driving and Operating Machinery**

COMIRNATY has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under [8 ADVERSE REACTIONS](#) may temporarily affect the ability to drive or use machines.

## **Fertility**

It is unknown whether this vaccine has an impact on fertility. Animal studies do not indicate direct or indirect harmful effects with respect to female fertility or reproductive toxicity (see [16 NON-CLINICAL TOXICOLOGY](#)).

## **Hematologic**

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.

## **Immune**

The efficacy and safety of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. Immunocompromised persons, including

individuals receiving immunosuppressant therapy, may have a diminished immune response to the vaccine.

## 7.1 Special Populations

### 7.1.1 Pregnant Women

No data are available yet regarding the use of COMIRNATY during pregnancy.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/fetal development, parturition, or post-natal development (see [16 NON-CLINICAL TOXICOLOGY](#)).

### 7.1.2 Breast-feeding

No data are available yet regarding the use of COMIRNATY during breast-feeding.

It is unknown whether COMIRNATY is excreted in human milk. A risk to the newborns/infants cannot be excluded.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for immunization against COVID-19.

### 7.1.3 Pediatrics

The safety and efficacy of COMIRNATY in children under 6 months of age have not yet been established.

### 7.1.4 Geriatrics

Clinical studies of COMIRNATY (Original) and COMIRNATY Original & Omicron BA.4/BA.5 included participants 65 years of age and older and their data contribute to the overall assessment of the safety and efficacy of COMIRNATY (See [8 ADVERSE REACTIONS](#) and [14 CLINICAL TRIALS](#)).

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

The safety of COMIRNATY is inferred from safety data of the prior COMIRNATY (Original) and COMIRNATY Original & Omicron BA.4/BA.5 vaccines.

Safety data accrued with the COMIRNATY (Original) and COMIRNATY Original & Omicron BA.4/BA.5 formulations are relevant to the subsequent variant updated COMIRNATY vaccines because these vaccines are manufactured using the same process.

#### 8.1.1 COMIRNATY Original & Omicron BA.4/BA.5 (15 mcg/15 mcg)

##### **Participants ≥12 Years of Age – After a Dose of COMIRNATY Original & Omicron BA.4/BA.5 as a Second Booster (4<sup>th</sup> Dose)**

Study C4591044 (Study 5) is an ongoing Phase 2/3 study to evaluate the safety, tolerability, and immunogenicity of new bivalent vaccines including COMIRNATY Original & Omicron BA.4/BA.5. In Cohorts 2 and 3 of the study 317 participants 12 years and older and 410 participants 18 years and older, respectively, received COMIRNATY Original & Omicron BA.4/BA.5 30 mcg (15/15 mcg) as a second booster dose following a previous primary series and one booster dose of COMIRNATY. The

safety evaluation of participants in the study is ongoing. All participants were monitored for solicited local and systemic reactions and use of antipyretic medication after vaccination with an electronic diary during the 7 days following the dose of vaccination. Participants continue to be monitored for unsolicited adverse events (AEs), including serious adverse events (SAEs), throughout the study [from Dose 1 to 1 month after the last dose (all AEs) and 6 months (SAEs) after the last vaccination].

In a substudy from Study 5, 108 participants 12 to 17 years of age, 313 participants 18 to 55 years of age and 306 participants ≥56 years of age who had completed 3 doses of COMIRNATY, received a booster (fourth dose) of COMIRNATY Original & Omicron BA.4/BA.5 (15/15 mcg) 5.4 to 16.9 months after receiving Dose 3. Participants who received a booster (fourth dose) of COMIRNATY Original & Omicron BA.4/BA.5 had a median follow-up time of at least 1.5 months.

The overall safety profile for the COMIRNATY Original & Omicron BA.4/BA.5 booster (fourth dose) was similar to that seen after 3 doses of COMIRNATY. The most frequent adverse reactions in participants 12 years of age and older were injection site pain (>60%), fatigue (>50%), headache (>40%), muscle pain (>20%), chills (>10%), and joint pain (>10%).

### **8.1.2 COMIRNATY Original & Omicron BA.4/BA.5 (5 mcg/5 mcg)**

#### **Participants 5 to <12 Years of Age – After a Dose of COMIRNATY Original & Omicron BA.4/BA.5 as a Second Booster (4<sup>th</sup> Dose)**

Study C4591048 (Study 6) is an ongoing study to evaluate the safety, tolerability, and immunogenicity of new bivalent vaccines including COMIRNATY Original & Omicron BA.4/BA.5.

In a subset from Study 6 (Phase 3), 113 participants 5 to <12 years of age who had completed 3 doses of COMIRNATY, received a booster (fourth dose) of COMIRNATY Original & Omicron BA.4/BA.5 (5/5 mcg) 2.6 to 8.5 months after receiving Dose 3. Participants who received a booster (fourth dose) of COMIRNATY Original & Omicron BA.4/BA.5 had a median follow-up time of at least 1.6 months.

The overall safety profile for the COMIRNATY Original & Omicron BA.4/BA.5 booster (fourth dose) was similar to that seen after 3 doses of COMIRNATY. The most frequent adverse reactions in participants 5 to <12 years were injection site pain (>60%), fatigue (>40%), headache (>20%), and muscle pain (>10%).

### **8.1.3 COMIRNATY Original & Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg)**

Study C4591048 (Study 6) is an ongoing study evaluating the safety, tolerability and immunogenicity of COMIRNATY Original & Omicron BA.4/BA.5. The safety of a 3-dose primary series of COMIRNATY Original & Omicron BA.4/BA.5 at 1.5 mcg/1.5 mcg in children 6 months to < 5 years of age is inferred primarily from the safety profile of COMIRNATY at 3 mcg administered as a 3-dose primary series in this age bracket. Safety data from study 6 in children 6 months to <5 years of age using the COMIRNATY Original & Omicron BA.4/BA.5 formulation at 1.5 mcg/1.5 mcg administered as a booster (fourth) dose are considered supportive.

#### **Participants 2 Years Through <5 Years of Age – After a Dose of COMIRNATY Original & Omicron BA.4/BA.5 as a Booster (4<sup>th</sup> Dose)**

In a subset from Study 6 (Phase 3), 124 participants 2 through <5 years of age who had completed 3 doses of COMIRNATY, received a booster of COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg) 2.2 to 8.6 months after receiving Dose 3. Participants who received a booster of COMIRNATY Original & Omicron BA.4/BA.5 had a median follow-up time of at least 1.8 months up to a data cut-off date of 30 Nov 2022.



The overall safety profile for the COMIRNATY Original & Omicron BA.4/BA.5 booster was similar to that seen after 3 doses of COMIRNATY. The most frequent adverse reactions in participants 2 through <5 years of age were injection site pain (>30%) and fatigue (>20%).

#### **Participants 6 months Through <2 Years of Age – After a Dose of COMIRNATY Original & Omicron BA.4/BA.5 as a Booster (4<sup>th</sup> Dose)**

In a subset from Study 6 (Phase 3), 39 participants 6 months to <2 years of age who had completed 3 doses of COMIRNATY, received a booster of COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg) 2.1 to 8.6 months after receiving Dose 3. Participants who received a booster of COMIRNATY Original & Omicron BA.4/BA.5 had a median follow-up time of at least 1.7 months up to data cut-off of 30 Nov 2022.

The overall safety profile for the COMIRNATY Original & Omicron BA.4/BA.5 booster was similar to that seen after 3 doses of COMIRNATY. The most frequent adverse reactions in participants 6 months to <2 years of age were irritability (>20%) and decreased appetite (>10%).

#### **8.1.4 COMIRNATY (Original: 30 mcg)**

Study BNT162-01 (Study 1) was a Phase 1/2, two-part dose-escalation trial that enrolled 60 participants 18 through 55 years of age and 36 participants 56 through 85 years of age.

Study C4591001 (Study 2) is a Phase 1/2/3, multicenter, multinational, randomized, saline placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection (Phase 1) and efficacy (Phase 2/3) study that has enrolled approximately 46,000 participants, 12 years of age or older. Of these, approximately 44,047 participants (22,026 COMIRNATY; 22,021 placebo) in Phase 2/3 are 16 years of age or older (including 378 and 376 adolescents 16 and 17 years of age in the vaccine and placebo groups, respectively) and 2,260 adolescents are 12 to 15 years of age (1,131 and 1,129 in the vaccine and placebo groups, respectively). Of the total number of COMIRNATY recipients in the study, 20.7% were 65 years of age and older. Study 2 also included 200 participants with confirmed stable human immunodeficiency virus (HIV) infection. HIV-positive participants are included in safety population disposition but are summarized separately in safety analyses.

Additionally, 306 existing Phase 3 participants 18 through 55 years of age received a booster dose of COMIRNATY approximately 6 months (range of 4.8 to 8.0 months) after completing the second dose in the non-placebo-controlled booster dose portion of Study 2. The overall safety profile for the booster dose was similar to that seen after 2 doses.

In Study C4591031 (Study 4), a placebo-controlled booster study, 5,081 participants 16 years of age and older were recruited from Study 2 to receive a booster dose of COMIRNATY at least 6 months after the second dose. The overall safety profile for the booster dose was similar to that seen after 2 doses.

The safety evaluation of participants in Study 2 and Study 4 is ongoing. In Study 2, all participants 12 to 15 years of age and 16 years of age and older in the reactogenicity subset, and a subset of 306 participants 18 through 55 years of age who received a booster dose in Study 2, were monitored for solicited local and systemic reactions and use of antipyretic medication after each vaccination with an electronic diary during the 7 days following any dose of vaccination. Participants, including those who received a booster in Study 4, continue to be monitored for unsolicited adverse events (AEs), including serious adverse events (SAEs), throughout the study [from Dose 1 to 1 month after the last dose (all AEs) and 6 months (SAEs) after the last vaccination].

### **Participants 12 Years of Age and Older**

At the time of the analysis of Study 2 (data accrued through March 13, 2021), a total of 25,651 (58.2%) participants (13,031 in vaccine group and 12,620 in placebo group) 16 years of age and older had been followed up for at least 4 months, with 3,082 (7.0%) participants (1,778 in vaccine group and 1,304 in placebo group) followed up for at least 6 months after the second dose during the blinded placebo-controlled follow-up period. A total of 12,006 (54.5%) participants originally randomized to the vaccine group in Study 2 had been followed up for at least 6 months after the second dose including the blinded and open-label periods.

In an analysis of Study 2, based on data up to the cut-off date of March 13, 2021, a total of 2,260 adolescents (1,131 COMIRNATY; 1,129 placebo) were 12 to 15 years of age. Of these, 1,559 (786 COMIRNATY and 773 placebo) adolescents have been followed for  $\geq 4$  months after the second dose of COMIRNATY.

In clinical studies with a data cut-off of March 13, 2021, and where 2 doses were administered 3 weeks apart, the most common adverse reactions in the reactogenicity subset ( $n=4,924$ ) of participants 16 years of age and older after any dose included injection site pain (84.3%), fatigue (64.7%), headache (57.1%), muscle pain (40.2%), chills (34.7%), joint pain (25.0%), fever (15.2%), injection site swelling (11.1%), and injection site redness (9.9%). Additional AEs reported in the safety population ( $n=21,926$ ) of participants 16 years of age and older from dose 1 to 1 month after dose 2 included nausea (1.2%), malaise (0.6%), lymphadenopathy (0.4%), asthenia (0.3%), decreased appetite (0.2%), hyperhidrosis (0.1%), lethargy (0.1%), and night sweats (0.1%). Adverse reactions were usually mild or moderate in intensity and resolved within a few days after vaccination.

The safety profile in 545 participants receiving COMIRNATY that were seropositive for SARS-CoV-2 at baseline was similar to that seen in the general population.

In a clinical study with a data cut-off date of 02 September 2021, the most commonly reported ( $\geq 8\%$ ) adverse reactions in adolescents 12 through 15 years of age following any dose were pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), and injection site redness (8.6%).

In a clinical study of participants 18 through 55 years of age ( $N=306$ ), 289 participants (94%) completed the e-diary recording adverse reactions. The most commonly reported adverse reactions ( $\geq 10\%$ ) following administration of a booster dose were pain at the injection site (83.0%), fatigue (63.7%), headache (48.4%), muscle pain (39.1%), chills (29.1%), and joint pain (25.3%).

In a clinical study of approximately 10,000 participants 16 years of age and older, unsolicited adverse reactions following administration of a booster dose included headache (5%), fever (4.8%), lymphadenopathy (2.8%), pain in extremity (1.1%), nausea (0.9%), malaise (0.7%), and decreased appetite (0.2%).

#### **8.1.5 COMIRNATY (Original: 10 mcg)**

Study C4591007 (Study 3) is a Phase 1/2/3 study comprised of an open-label vaccine dose-finding portion (Phase 1) and a multicenter, multinational, randomized, saline placebo-controlled, observer-blind immunogenicity and efficacy portion (Phase 2/3) that has enrolled approximately 4,600 participants 5 years through  $<12$  years of age. Of these, approximately 3,100 participants received COMIRNATY 10 mcg and approximately 1,500 participants received placebo in the Phase 2/3 part of the study. Study 3 also enrolled 1,776 participants 6 months through  $<2$  years of age (1,178 COMIRNATY 3

mcg; 598 placebo), and 2,750 participants 2 through <5 years of age (1,835 COMIRNATY 3 mcg; 915 placebo) in Phase 2/3.

In a subset of Study 3 Phase 2/3 participants, 401 participants 5 years through <12 years of age received a booster dose of COMIRNATY at least 5 months (range 5 to 9 months) after completing the primary series. The overall safety profile for the booster dose was similar to that seen after the primary series. The analysis of the Study 3 Phase 2/3 subset is based on data up to the cut-off date of March 22, 2022 (median follow-up time of 1.3 months).

#### **Participants 5 Years Through <12 Years of Age**

In an analysis of Study 3 Phase 2/3, based on data up to the cut-off date of October 8, 2021, 2,268 participants (initial enrolment group: 1,518 COMIRNATY 10 mcg and 750 placebo) were 5 years through <12 years of age. Of these, 2,171 (95.7%) (1,456 COMIRNATY 10 mcg and 715 placebo) participants have been followed for at least 3 months after Dose 2. An analysis of Study 3 Phase 2/3 adverse event data also included another 2,379 participants (safety expansion group: 1,591 COMIRNATY 10 mcg and 788 placebo), of whom 71.2% had a follow-up period for at least 2 weeks after Dose 2. The safety evaluation in Study 3 is ongoing.

Adverse reactions following administration of any dose in the initial enrolment safety population (n = 1,518) of children 5 years through <12 years of age included pain at the injection site (84.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), rash (0.5%), nausea (0.4%), malaise (0.1%), and decreased appetite (0.1%).

The most frequent adverse reactions in participants 5 years through <12 years of age following the booster dose (data cut-off date of March 22, 2022; median follow-up time of 1.3 months) were injection site pain (73.9%), fatigue (45.6%), headache (34.0%), myalgia (18.3%), chills (10.5%), injection site redness (15.6%), and swelling (16.4%). The most frequently reported unsolicited adverse event was lymphadenopathy (2.5%).

### **8.1.6 COMIRNATY (Original: 3 mcg)**

#### **Participants 2 Through <5 Years of Age**

Study 3 (Phase 2/3) enrolled 2,750 participants 2 through <5 years of age (1,835 COMIRNATY 3 mcg; 915 placebo). Of these, 2,726 participants (1,819 COMIRNATY 3 mcg; 907 placebo) received 2 doses and 1,369 (50.2%; 910 COMIRNATY 3 mcg and 459 placebo) participants have been followed for at least 4 months after the second dose; 886 participants received a 3-dose primary series (606 COMIRNATY 3 mcg; 280 placebo) and have been followed for a median of 1.4 months after the third dose, based on data in the blinded, placebo-controlled follow-up period up to the cut-off date of April 29, 2022. Adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

#### **Participants 6 Months Through <2 Years of Age**

Study 3 (Phase 2/3) also enrolled 1,776 participants 6 months through <2 years of age (1,178 COMIRNATY 3 mcg; 598 placebo). Of these, 1,762 participants (1,166 COMIRNATY 3 mcg; 596 placebo) received 2 doses and 1,207 (68.5%; 801 COMIRNATY 3 mcg and 406 placebo) participants have been followed for at least 4 months after the second dose; 570 participants received a 3-dose primary series (386 COMIRNATY 3 mcg; 184 placebo) and have been followed for a median of 1.3 months after the

third dose, based on data in the blinded, placebo-controlled follow-up period up to the cut-off date of April 29, 2022. Adverse reactions following administration of any dose included irritability (68.4%), decreased appetite (38.6%), tenderness at the injection site (26.4%), injection site redness (17.8%), fever (14.4%), injection site swelling (7.3%), and lymphadenopathy (0.2%).

## 8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials, therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

### 8.2.1 COMIRNATY Original & Omicron BA.4/BA.5 (15 mcg/15 mcg)

#### Participants 12 Years of Age and Older

##### Solicited Local Adverse Reactions

Table 2 presents the frequency of reported solicited local reactions within 7 days of a second booster dose with COMIRNATY Original & Omicron BA.4/BA.5.

Most local reactions were mild or moderate in severity and no Grade 4 local reactions were reported in any group. The median onset for all local reactions was 1 to 3 days, and all events resolved within a median duration of 1 to 3 days after onset.

**Table 2: Study 5 - Solicited Local Adverse Reactions Reported for Vaccine Groups Within 7 Days After Study Vaccination**

Local Reaction	COMIRNATY Original & Omicron BA.4/BA.5 (15 mcg/15 mcg)		
	12– 17 years N <sup>a</sup> =107 n <sup>b</sup>	18 – 55 years (N <sup>a</sup> =310) n <sup>b</sup>	>55 years (N <sup>a</sup> =300) n <sup>b</sup>
Redness <sup>c</sup>			
Any	6 (5.6)	21 (6.8)	11 (3.7)
Severe	0	0	0
Swelling <sup>c</sup>			
Any	8 (7.5)	23 (7.4))	8 (2.7)
Severe	0	0	0
Pain at the injection site <sup>d</sup>			
Any	75 (70.1)	236 (76.1)	172 (57.1) <sup>e</sup>
Severe	1 (0.9)	0	1 (0.3) <sup>e</sup>
Any local reaction <sup>f</sup>	75 (70.1)	240 (77.4)	174 (57.8) <sup>e</sup>

a. N = number of participants reporting at least 1 yes or no response for the specified reaction after the study vaccination.

b. n = Number of participants with the specified characteristic.

c. Mild: >2.0 to 5.0 cm; moderate: >5.0 to 10.0 cm; severe: >10.0 cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis (redness category only).

d. Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.

e. N=301

f. Any local reaction: any redness >2.0 cm, any swelling >2.0 cm, or any pain at the injection site.

### Solicited Systemic Adverse Reactions

Table 3 presents the frequency of reported systemic reactions within 7 days of a second booster dose of COMIRNATY Original & Omicron BA.4/BA.5. Most systemic reactions were mild or moderate in severity and no Grade 4 systemic reactions were reported in any group. The median onset for all systemic reactions was 2 to 4 days, and all events resolved within a median duration of 1 to 2 days after onset.

**Table 3: Study 5 - Solicited Systemic Adverse Reactions Reported for Vaccine Groups Within 7 Days After Study Vaccination**

Systemic Reaction	COMIRNATY Original & Omicron BA.4/BA.5 (15 mcg/15 mcg)		
	12– 17 years N <sup>a</sup> =107 n <sup>b</sup>	18 – 55 years (N <sup>a</sup> =309) n <sup>b</sup>	>55 years (N <sup>a</sup> =300) n <sup>b</sup>
Fever			
≥38.0°C	10 (9.3)	15 (4.9)	13 (4.3)
≥38.9°C to 40.0°C	1 (0.9)	0	0
Fatigue <sup>c</sup>			
Any	72 (67.3)	189 (61.2)	116 (38.5) <sup>d</sup>
Severe	0	6 (1.9)	4 (1.3) <sup>d</sup>
Headache <sup>c</sup>			
Any	54 (50.5)	144 (46.6)	92 (30.7)
Severe	0	2 (0.6)	0
Chills <sup>c</sup>			
Any	25 (23.4)	68 (22.0)	36 (12.0)
Severe	0	2 (0.6)	1 (0.3)
Vomiting <sup>e</sup>			
Any	3 (2.8)	6 (1.9)	29 (2.7)
Severe	0	0	0
Diarrhea <sup>f</sup>			
Any	7 (6.5)	33 (10.7)	29 (9.6) <sup>d</sup>
Severe	0	1 (0.3)	0 <sup>d</sup>
New or worsened muscle pain <sup>c</sup>			
Any	28 (26.2)	94 (30.4)	54 (18.0)
Severe	0	0	0
New or worsened joint pain <sup>c</sup>			
Any	13 (12.1))	46 (14.9)	36 (12.0)
Severe	1 (0.9)	0	0
Any systemic event <sup>g</sup>	86 (80.4)	229 (74.1)	12 (53.8) <sup>d</sup>
Use of antipyretic or pain medication <sup>h</sup>	36 (33.6)	105 (34.0)	74 (24.7)

a. N = number of participants reporting at least 1 yes or no response for the specified event after the study vaccination.

b. n = Number of participants with the specified characteristic.

c. Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe fatigue, severe headache, severe chills, severe muscle pain, or severe joint pain.

d. N=301

- e. Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration; Grade 4: emergency room visit or hospitalization for severe vomiting.
- f. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours; Grade 4: emergency room visit or hospitalization for severe diarrhea.
- g. Any systemic event: any fever, any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any new or worsened joint pain.
- h. Severity was not collected for use of antipyretic or pain medication.

### Unsolicited Adverse Events

Among participants 12 years of age and older, unsolicited adverse events were reported by 48 (6.6%) participants who received a second booster dose through 1 month after the booster dose. Lymphadenopathy occurred in 7 (1.0%) participants.

## **8.2.2 COMIRNATY Original & Omicron BA.4/BA.5 (5 mcg/5 mcg)**

### **Participants 5 to <12 Years of Age**

#### Solicited Local Adverse Reactions

Table 4 presents the frequency of reported solicited local reactions within 7 days of a second booster dose with COMIRNATY Original & Omicron BA.4/BA.5.

All local reactions were mild or moderate in severity. The median onset for all local reactions was 1 to 2 days, and all events resolved within a median duration of 2 days after onset.

**Table 4: Study 6 - Solicited Local Adverse Reactions Reported Within 7 Days After Study Vaccination**

<b>Local Reaction</b>	<b>COMIRNATY Original &amp; Omicron BA.4/BA.5 (5 mcg/5 mcg) (N=111)<sup>a</sup> n<sup>b</sup> %</b>
<b>Redness<sup>c</sup></b>	
Any	8 (7.2)
Severe	0
<b>Swelling<sup>c</sup></b>	
Any	5 (4.5)
Severe	0
<b>Pain at the injection site<sup>d</sup></b>	
Any	71 (64.0)
Severe	0
<b>Any local reaction<sup>e</sup></b>	<b>74 (66.7)</b>

a. N = number of participants reporting at least 1 yes or no response for the specified reaction after the study vaccination.

b. n = Number of participants with the specified characteristic.

c. Mild: ≥0.5 to 2.0 cm; moderate: >2.0 to 7.0 cm; severe: >7.0 cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis (redness category only).

d. Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.

e. Any local reaction: any redness ≥0.5 cm, any swelling ≥0.5 cm, or any pain at the injection site.

### Solicited Systemic Adverse Reactions

Table 5 presents the frequency of reported solicited systemic reactions within 7 days of a second booster dose with COMIRNATY Original & Omicron BA.4/BA.5.

Most systemic events were mild or moderate in severity, and no Grade 4 systemic events were reported. The median onset for all systemic events was 2 to 4 days, and all events resolved within a median duration of 1 to 2 days after onset.

**Table 5: Study 6 - Solicited Systemic Adverse Reactions Reported Within 7 Days After Study Vaccination**

Systemic Reaction	COMIRNATY Original & Omicron BA.4/BA.5 (5 mcg/5 mcg) (N=111) <sup>a</sup> n <sup>b</sup> %
Fever	
≥38.0°C	5 (4.5)
≥38.9°C to 40.0°C	2 (1.8)
Fatigue <sup>c</sup>	
Any	45 (40.5)
Severe	1 (0.9)
Headache <sup>c</sup>	
Any	28 (25.2)
Severe	1 (0.9)
Chills <sup>c</sup>	
Any	10 (9.0)
Severe	0
Vomiting <sup>d</sup>	
Any	4 (3.6)
Severe	0
Diarrhea <sup>e</sup>	
Any	4 (3.6)
Severe	0
New or worsened muscle pain <sup>c</sup>	
Any	15 (13.5)
Severe	0
New or worsened joint pain <sup>c</sup>	
Any	10 (9.0)
Severe	0
Any systemic event <sup>f</sup>	58 (52.3)
Use of antipyretic or pain medication <sup>g</sup>	26 (23.4)

a. N = number of participants reporting at least 1 yes or no response for the specified event after the study vaccination.

b. n = Number of participants with the specified characteristic.

c. Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or

hospitalization for severe fatigue, severe headache, severe chills, severe muscle pain, or severe joint pain.

d. Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration; Grade 4: emergency room visit or hospitalization

for severe vomiting.

e. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours; Grade 4: emergency room visit or hospitalization for severe diarrhea.

f. Any systemic event: any fever  $\geq 38.0^{\circ}\text{C}$ , any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any new or worsened joint pain.

g. Severity was not collected for use of antipyretic or pain medication.

### Unsolicited Adverse Events

Among participants 5 to <12 years of age, unsolicited adverse events were reported by 4 (3.5%) participants who received a second booster dose through 1 month after the booster dose.

Lymphadenopathy occurred in 1 (0.9%) participant.

### **8.2.3 COMIRNATY Original & Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg)**

#### **Participants 2 Through <5 Years of Age – After a Dose of COMIRNATY Original & Omicron BA.4/BA.5 as a Booster (4<sup>th</sup> Dose)**

#### Solicited Local Adverse Reactions

Table 6 presents the frequency of solicited local reactions within 7 days of a booster (fourth) dose with COMIRNATY Original & Omicron BA.4/BA.5. Most local reactions were mild or moderate in severity. No severe or Grade 4 local reactions were reported. The onset for all local reactions was 1 to 2 days, and all events resolved within 1 to 3 days after onset.

**Table 6: Study 6 - Solicited Local Adverse Reactions Reported Within 7 Days After a Booster (Fourth Dose) – Participants 2 Through <5 Years of Age – Safety Population**

Local Reaction	COMIRNATY Original & Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg) (N=124) <sup>a</sup> n <sup>b</sup> %
Redness <sup>c</sup>	
Any	10 (8.1))
Severe	0
Swelling <sup>c</sup>	
Any	7 (5.6)
Severe	0
Pain at the injection site <sup>d</sup>	
Any	39 (31.5)
Severe	0
Any local reaction <sup>e</sup>	48 (38.7)

a. N = number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. n = Number of participants with the specified characteristic.

c. Mild:  $\geq 0.5$  to 2.0 cm; moderate:  $>2.0$  to 7.0 cm; severe:  $>7.0$  cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis (redness category only).

d. Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.

e. Any local reaction: any redness  $\geq 0.5$  cm, any swelling  $\geq 0.5$  cm, or any pain at the injection site.



### Solicited Systemic Adverse Reactions

Table 7 presents the frequency of solicited systemic reactions within 7 days of a booster (fourth) dose with COMIRNATY Original & Omicron BA.4/BA.5. Most systemic reactions were mild or moderate in severity. No severe or Grade 4 systemic reactions were reported. The median onset for most systemic reactions was 1 to 6 days, and most events resolved within a median duration of 1 to 2 days after onset.

**Table 7: Study 6 - Solicited Systemic Reactions Reported Within 7 Days After a Booster (Fourth Dose) – Participants 2 Through <5 Years of Age – Safety Population**

Systemic Reaction	COMIRNATY Original & Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg) (N=123) <sup>a</sup> n <sup>b</sup> %
Fever	
≥38.0°C	6 (4.8) <sup>c</sup>
≥38.9°C to 40.0°C	0 <sup>c</sup>
Fatigue <sup>d</sup>	
Any	36 (29.3)
Severe	0
Headache <sup>d</sup>	
Any	5 (4.1)
Severe	2 (1.6)
Chills <sup>d</sup>	
Any	7 (5.7)
Severe	0
Vomiting <sup>e</sup>	
Any	7 (5.7)
Severe	0
Diarrhea <sup>f</sup>	
Any	6 (4.9)
Severe	0
New or worsened muscle pain <sup>d</sup>	
Any	4 (3.3)
Severe	0
New or worsened joint pain <sup>d</sup>	
Any	2 (1.6)
Severe	0
Any systemic event <sup>g</sup>	45 (36.3) <sup>c</sup>
Use of antipyretic or pain medication <sup>h</sup>	14 (11.3) <sup>c</sup>

a. N = number of participants reporting at least 1 yes or no response for the specified event after the study vaccination.

b. n = Number of participants with the specified characteristic.

c. N = 124

d. Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe fatigue, severe headache, severe chills, severe new or worsened muscle pain, or severe new or worsened joint pain.

- e. Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration; Grade 4: emergency room visit or hospitalization for hypotensive shock.
- f. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours; Grade 4: emergency room visit or hospitalization for severe diarrhea.
- g. Any systemic event: any fever  $\geq 38.0^{\circ}\text{C}$ , any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any new or worsened joint pain.
- h. Severity was not collected for use of antipyretic or pain medication.

### **Participants 6 Months Through <2 Years of Age**

#### **Solicited Local Adverse Reactions**

Table 8 presents the frequency of solicited local reactions within 7 days of a booster (fourth) dose with COMIRNATY Original & Omicron BA.4/BA.5. All local reactions were mild in severity. No moderate, severe or Grade 4 local reactions were reported. The onset for all local reactions was 1 day, and all events resolved within 1 day after onset.

**Table 8: Study 6 - Solicited Local Adverse Reactions Reported Within 7 Days After a Booster (Fourth Dose) – Participants 6 Months Through <2 Years of Age – Safety Population**

<b>Local Reaction</b>	<b>COMIRNATY Original &amp; Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg) (N=39)<sup>a</sup> n<sup>b</sup> %</b>
Redness <sup>c</sup>	
Any	2 (5.1)
Severe	0
Swelling <sup>c</sup>	
Any	1 (2.6)
Severe	0
Tenderness at the injection site <sup>d</sup>	
Any	2 (5.3) <sup>e</sup>
Severe	0 <sup>e</sup>
Any local reaction <sup>f</sup>	3 (7.7)

a. N = number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. n = Number of participants with the specified characteristic.

c. Mild:  $\geq 0.5$  to 2.0 cm; moderate: >2.0 to 7.0 cm; severe: >7.0 cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis (redness category only).

d. Mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: causes limitation of limb movement; Grade 4: emergency room visit or hospitalization for severe pain (tenderness) at the injection site.

e. N = 38

f. Any local reaction: any redness  $\geq 0.5$  cm, any swelling  $\geq 0.5$  cm, or any pain at the injection site.

#### **Solicited Systemic Adverse Reactions**

Table 9 presents the frequency of solicited systemic reactions within 7 days of a booster (fourth) dose with COMIRNATY Original & Omicron BA.4/BA.5. Most systemic reactions were mild or moderate in severity. No severe or Grade 4 systemic reactions were reported. The median onset for all systemic reactions was 2 to 6 days, and most events resolved within a median duration of 1 to 3 days after onset.

**Table 9: Study 6 - Solicited Systemic Reactions Reported Within 7 Days After a Booster (Fourth Dose) – Participants 6 Months Through <2 Years of Age – Safety Population**

Systemic Reaction	COMIRNATY Original & Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg) (N=39) <sup>a</sup> n <sup>b</sup> %
Fever	
≥38.0°C	2 (5.1)
≥38.9°C to 40.0°C	0
Decreased appetite <sup>c</sup>	
Any	7 (18.9) <sup>d</sup>
Severe	0 <sup>d</sup>
Drowsiness <sup>e</sup>	
Any	4 (10.8) <sup>d</sup>
Severe	0 <sup>d</sup>
Irritability <sup>f</sup>	
Any	11 (29.7) <sup>d</sup>
Severe	0 <sup>d</sup>
Any systemic event <sup>g</sup>	13 (33.3)
Use of antipyretic or pain medication <sup>h</sup>	3 (7.7)

a. N = number of participants reporting at least 1 yes or no response for the specified event after the study vaccination.

b. n = Number of participants with the specified characteristic.

c. Mild: decreased interest in eating; Moderate: decreased oral intake; Severe: refusal to feed; Grade 4: emergency room visit or hospitalization for severe decreased appetite (loss of appetite).

d. N=37

e. Mild: increased or prolonged sleeping bouts; Moderate: slightly subdued interfering with daily activity; Severe: disabling; not interested in usual daily activity; Grade 4: emergency room visit or hospitalization for severe drowsiness (increased sleep).

f. Mild: easily consolable; moderate: requiring increased attention; severe: inconsolable; crying cannot be comforted; Grade 4: emergency room visit or hospitalization for severe irritability (fussiness).

g. Any systemic event: any fever ≥38.0°C, any decreased appetite, any drowsiness, or any irritability.

h. Severity was not collected for use of antipyretic or pain medication.

### Unsolicited Adverse Events

The safety population included 39 participants ≥6 months to <2 years of age and 124 participants ≥2 years to <5 years of age who received a fourth dose of COMIRNATY Original & Omicron BA.4/BA.5 at 3 mcg. Overall, median (min, max) follow-up time after study vaccination was 1.8 (1.3, 2.5) months.

Overall, AEs were reported by 6 (15.4%) and 6 (4.8%) participants in the ≥6 months to <2 years of age group and ≥2 to <5 years of age group, respectively. No severe AEs, life-threatening AEs, SAEs, or AEs leading to withdrawal or death were reported from study vaccination to 1 month after study vaccination.

From study vaccination through 1-month postvaccination, no AEs of lymphadenopathy, rash, anaphylaxis/hypersensitivity, appendicitis, Bell's palsy, and myo/pericarditis were reported.

## 8.2.4 COMIRNATY (Original: 30 mcg)

### Participants 16 Years of Age and Older – Primary Series (Two Doses)

#### Solicited Adverse Reactions

Tables 10 through 13 present the frequency and severity of solicited local and systemic reactions, respectively, within 7 days following each dose of COMIRNATY and placebo in the subset of participants 16 years of age and older (n=9,839) in the safety population who were monitored for reactogenicity with an electronic diary.

**Table 10: Study 2 – Frequency of Solicited Local Reactions Within 7 Days After Each Dose of COMIRNATY– Participants 16-55 Years of Age (Reactogenicity Subset of the Safety Population\*)**

Local Reaction	Dose 1		Dose 2	
	COMIRNATY <sup>‡</sup> N <sup>a</sup> =2,899 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =2,908 n <sup>b</sup> (%)	COMIRNATY <sup>‡</sup> N <sup>a</sup> =2,682 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =2,684 n <sup>b</sup> (%)
Redness				
Any <sup>c</sup>	156 (5.4)	28 (1.0)	151 (5.6)	18 (0.7)
Severe <sup>d</sup>	7 (0.2)	3 (0.1)	11 (0.4)	0 (0.0)
Swelling				
Any <sup>c</sup>	184 (6.3)	16 (0.6)	183 (6.8)	5 (0.2)
Severe <sup>d</sup>	6 (0.2)	2 (0.1)	7 (0.3)	0 (0.0)
Pain at the injection site				
Any <sup>c</sup>	2,426 (83.7)	414 (14.2)	2,101 (78.3)	312 (11.6)
Severe <sup>e</sup>	39 (1.3)	3 (0.1)	39 (1.5)	0 (0.0)
Any local reaction <sup>c</sup>	2,444 (84.3)	432 (14.9)	2,108 (78.6)	325 (12.1)

\*Randomized participants in the safety analysis population who received at least 1 dose of the study intervention.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. No Grade 4 solicited local reactions were reported in participants 16-55 years of age.

b. n = Number of participants with the specified reaction.

c. Any local reaction: any redness >2.0 cm, any swelling >2.0 cm, or any pain at the injection site.

d. Severe: >10.0 cm.

e. Severe: prevents daily activity.

**Table 11: Study 2 – Frequency of Solicited Systemic Reactions Within 7 Days After Each Dose of COMIRNATY – Participants 16-55 Years of Age (Reactogenicity Subset of the Safety Population\*)**

Systemic Reaction	Dose 1		Dose 2	
	COMIRNATY <sup>‡</sup> N <sup>a</sup> =2,899 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =2,908 n <sup>b</sup> (%)	COMIRNATY <sup>‡</sup> N <sup>a</sup> =2,682 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =2,684 n <sup>b</sup> (%)
Fever				
≥38.0°C	119 (4.1)	25 (0.9)	440 (16.4)	11 (0.4)
>38.9°C	8 (0.3)	4 (0.1)	40 (1.5)	2 (0.1)
Fatigue				
Any	1,431 (49.4)	960 (33.0)	1,649 (61.5)	614 (22.9)
Severe <sup>d</sup>	41 (1.4)	18 (0.6)	142 (5.3)	14 (0.5)
Headache				
Any	1,262 (43.5)	975 (33.5)	1,448 (54.0)	652 (24.3)
Severe <sup>d</sup>	33 (1.1)	24 (0.8)	91 (3.4)	18 (0.7)
Chills				
Any	479 (16.5)	199 (6.8)	1,015 (37.8)	114 (4.2)
Severe <sup>d</sup>	15 (0.5)	2 (0.1)	69 (2.6)	2 (0.1)
Vomiting				
Any	34 (1.2)	36 (1.2)	58 (2.2)	30 (1.1)
Severe <sup>e</sup>	0 (0.0)	1 (0.0)	4 (0.1)	0 (0.0)
Diarrhea				
Any	309 (10.7)	323 (11.1)	269 (10.0)	205 (7.6)
Severe <sup>f</sup>	3 (0.1)	1 (0.0)	6 (0.2)	1 (0.0)
New or worsened muscle pain				
Any	664 (22.9)	329 (11.3)	1,055 (39.3)	237 (8.8)
Severe <sup>d</sup>	15 (0.5)	2 (0.1)	62 (2.3)	3 (0.1)
New or worsened joint pain				
Any	342 (11.8)	168 (5.8)	638 (23.8)	147 (5.5)
Severe <sup>d</sup>	5 (0.2)	1 (0.0)	27 (1.0)	4 (0.1)
Any systemic reaction <sup>c</sup>	1,979 (68.3)	1,559 (53.6)	2,034 (75.8)	1,026 (38.2)
Use of antipyretic or pain medication	805 (27.8)	398 (13.7)	1,213 (45.2)	320 (11.9)

\*Randomized participants in the safety analysis population who received at least 1 dose of the study intervention.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. No Grade 4 solicited systemic reactions were reported in participants 16-55 years of age.

b. n = Number of participants with the specified reaction.

c. Any systemic reaction: any fever ≥38.0°C, any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any new or worsened joint pain.

d. Severe: prevents daily activity.

e. Severe: requires intravenous hydration.

f. Severe: 6 or more loose stools in 24 hours.

**Table 12: Study 2 – Frequency of Solicited Local Reactions Within 7 Days After Each Dose of COMIRNATY – Participants 56 Years of Age and Older (Reactogenicity Subset of the Safety Population\*)**

Local Reaction	Dose 1		Dose 2	
	COMIRNATY <sup>‡</sup> N <sup>a</sup> =2,008 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =1,989 n <sup>b</sup> (%)	COMIRNATY <sup>‡</sup> N <sup>a</sup> =1,860 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =1,833 n <sup>b</sup> (%)
Redness				
Any <sup>c</sup>	106 (5.3)	20 (1.0)	133 (7.2)	14 (0.8)
Severe <sup>d</sup>	5 (0.2)	2 (0.1)	10 (0.5)	1 (0.1)
Swelling				
Any <sup>c</sup>	141 (7.0)	23 (1.2)	145 (7.8)	13 (0.7)
Severe <sup>d</sup>	2 (0.1)	0 (0.0)	4 (0.2)	1 (0.1)
Pain at the injection site				
Any <sup>c</sup>	1,408 (70.1)	185 (9.3)	1,230 (66.1)	143 (7.8)
Severe <sup>e</sup>	4 (0.2)	0 (0.0)	10 (0.5)	0 (0.0)
Any local reaction <sup>c</sup>	1,433 (71.4)	207 (10.4)	1,243 (66.8)	158 (8.6)

\*Randomized participants in the safety analysis population who received at least 1 dose of the study intervention.

<sup>‡</sup>Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. No Grade 4 solicited local reactions were reported in participants 56 years of age and older.

b. n = Number of participants with the specified reaction.

c. Any local reaction: any redness >2.0 cm, any swelling >2.0 cm, or any pain at the injection site.

d. Severe: >10.0 cm.

e. Severe: prevents daily activity.

**Table 13: Study 2 – Frequency of Solicited Systemic Reactions Within 7 Days After Each Dose of COMIRNATY – Participants 56 Years of Age and Older (Reactogenicity Subset of the Safety Population\*)**

Systemic Reaction	Dose 1		Dose 2	
	COMIRNATY <sup>‡</sup> N <sup>a</sup> =2,008 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =1,989 n <sup>b</sup> (%)	COMIRNATY <sup>‡</sup> N <sup>a</sup> =1,860 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =1,833 n <sup>b</sup> (%)
Fever				
≥38.0°C	26 (1.3)	8 (0.4)	219 (11.8)	4 (0.2)
>38.9°C	1 (0.0)	2 (0.1)	7 (0.4)	1 (0.1)
Fatigue				
Any	677 (33.7)	447 (22.5)	949 (51.0)	306 (16.7)
Severe <sup>d</sup>	3 (0.1)	3 (0.2)	60 (3.2)	2 (0.1)
Grade 4 <sup>g</sup>	0 (0.0)	0 (0.0)	1 (0.1)	0 (0.0)
Headache				
Any	503 (25.0)	363 (18.3)	733 (39.4)	259 (14.1)
Severe <sup>d</sup>	2 (0.1)	3 (0.2)	13 (0.7)	5 (0.3)
Chills				
Any	130 (6.5)	69 (3.5)	435 (23.4)	57 (3.1)

**Table 13: Study 2 – Frequency of Solicited Systemic Reactions Within 7 Days After Each Dose of COMIRNATY – Participants 56 Years of Age and Older (Reactogenicity Subset of the Safety Population\*)**

Systemic Reaction	Dose 1		Dose 2	
	COMIRNATY <sup>‡</sup> N <sup>a</sup> =2,008 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =1,989 n <sup>b</sup> (%)	COMIRNATY <sup>‡</sup> N <sup>a</sup> =1,860 n <sup>b</sup> (%)	Placebo N <sup>a</sup> =1,833 n <sup>b</sup> (%)
Severe <sup>d</sup>	0 (0.0)	1 (0.1)	21 (1.1)	0 (0.0)
Vomiting				
Any	10 (0.5)	9 (0.5)	13 (0.7)	5 (0.3)
Severe <sup>e</sup>	0 (0.0)	0 (0.0)	2 (0.1)	0 (0.0)
Diarrhea				
Any	168 (8.4)	130 (6.5)	152 (8.2)	102 (5.6)
Severe <sup>f</sup>	4 (0.2)	1 (0.1)	2 (0.1)	4 (0.2)
New or worsened muscle pain				
Any	274 (13.6)	165 (8.3)	537 (28.9)	99 (5.4)
Severe <sup>d</sup>	1 (0.0)	3 (0.2)	20 (1.1)	1 (0.1)
New or worsened joint pain				
Any	175 (8.7)	124 (6.2)	353 (19.0)	72 (3.9)
Severe <sup>d</sup>	3 (0.1)	1 (0.1)	9 (0.5)	1 (0.1)
Any systemic reaction <sup>c</sup>	984 (49.0)	749 (37.7)	1,203 (64.7)	516 (28.2)
Use of antipyretic or pain medication	382 (19.0)	224 (11.3)	688 (37.0)	170 (9.3)

\*Randomized participants in the safety analysis population who received at least 1 dose of the study intervention.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. The only Grade 4 solicited systemic reaction reported in participants 56 years of age and older was fatigue.

b. n = Number of participants with the specified reaction.

c. Any systemic reaction: any fever  $\geq 38.0^{\circ}\text{C}$ , any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any new or worsened joint pain.

d. Severe: prevents daily activity.

e. Severe: requires intravenous hydration.

f. Severe: 6 or more loose stools in 24 hours.

g. Grade 4: emergency room visit or hospitalization.

Study 2 also included 200 participants with confirmed stable human immunodeficiency virus (HIV) infection. The safety profile of the participants with stable HIV infection receiving COMIRNATY (n = 100) was similar to that seen in the general population.

#### Unsolicited Adverse Events

The participants were unblinded to offer placebo participants COMIRNATY when they became locally eligible under regulatory approval in December 2020. A total of 25,651 (58.2%) participants (13,031 in vaccine group and 12,620 in placebo group) 16 years of age and older had been followed up for at least 4 months, with 3,082 (7.0%) participants (1,778 in vaccine group and 1,304 in placebo group) followed up for at least 6 months after the second dose during the blinded placebo-controlled follow-up period in Study 2. Adverse events detailed below for participants 16 years of age and older are for the placebo-controlled blinded follow-up period up to the participants' unblinding dates.

Among participants 16 through 55 years of age who received at least one dose of study vaccine, 12,995 of whom received COMIRNATY and 13,026 of whom received placebo, unsolicited adverse events were reported by 4,396 (33.8%) participants in the COMIRNATY group and 2,136 (16.4%) participants in the placebo group. In a similar analysis in participants 56 years of age and older that included 8,931 COMIRNATY recipients and 8,895 placebo recipients, unsolicited adverse events were reported by 2,551 (28.6%) participants in the COMIRNATY group and 1,432 (16.1%) participants in the placebo group. Among participants with confirmed stable HIV infection that included 100 COMIRNATY recipients and 100 placebo recipients, unsolicited adverse events were reported by 29 (29%) participants in the COMIRNATY group and 15 (15%) participants in the placebo group.

Lymphadenopathy was reported in 87 (0.4%) participants in the vaccine group compared to 8 (<0.1%) participants in the placebo group. Bell's palsy (facial paralysis and facial paresis) was reported by four participants in the vaccine group and two in the placebo group. In the four vaccinated participants, events began from 3 to 48 days after their last dose, were mild to moderate in severity, and duration ranged from 3 to 68 days. Currently available information is insufficient to determine a causal relationship with the vaccine. There were no other notable patterns or numerical imbalances between treatment groups for specific categories of non-serious adverse events (including other neurologic or neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. Cumulative safety follow-up to at least 6 months after Dose 2 for approximately 12,000 participants who received COMIRNATY showed no other safety signals arising from longer-term follow-up of the study.

#### *Serious Adverse Events*

In Study 2, among participants 16 through 55 years of age who had received at least 1 dose of vaccine or placebo (COMIRNATY = 12,995; placebo = 13,026), serious adverse events from Dose 1 up to the participant unblinding date in ongoing follow-up were reported by 103 (0.8%) COMIRNATY recipients and 117 (0.9%) placebo recipients. In a similar analysis, in participants 56 years of age and older (COMIRNATY = 8,931; placebo = 8,895), serious adverse events were reported by 165 (1.8%) COMIRNATY recipients and 151 (1.7%) placebo recipients who received at least 1 dose of COMIRNATY or placebo, respectively. Among participants with confirmed stable HIV infection serious adverse events from Dose 1 up to the participant unblinding date in ongoing follow-up were reported by 2 (2%) COMIRNATY recipients and 2 (2%) placebo recipients.

Pericarditis was reported for one participant in the vaccine group, and no case was reported in the placebo group. Appendicitis was reported as a serious adverse event for 27 participants, 15 vaccine participants and 12 placebo participants. Currently available information is insufficient to determine a causal relationship with the vaccine. There were no other notable patterns or numerical imbalances between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, thrombotic events, myocarditis or anaphylactic reaction to the vaccine) reported during the blinded placebo-controlled follow-up period of the study.

#### **Participants 16 Years of Age and Older – After Booster Dose**

A subset from Study C4591001 (Study 2) Phase 2/3 participants, of 306 adults 18 through 55 years of age who completed the original COMIRNATY 2-dose series, received a booster dose of COMIRNATY approximately 6 months (range of 4.8 to 8.0 months) after receiving Dose 2.

In Study C4591031 (Study 4), a placebo-controlled booster study, participants 16 years of age and older recruited from Study C4591001 (Study 2) received a booster dose of COMIRNATY (5,081 participants), or placebo (5,044 participants) at least 6 months after the second dose of COMIRNATY. Overall,



participants who received a booster dose, had a median follow-up time of 2.5 months after the booster dose to the cut-off date (5 October 2021). Among the participants, the median age was 53.0 years (range 16 through 87 years of age), including 1,175 booster dose recipients (23.1%) who were ≥65 years of age, 49.1% were male and 50.9% were female, 79.0% were White, 14.9% were Hispanic/Latino, 9.2% were Black or African American, 5.5% were Asian, and 1.7% were American Indian/Alaska Native.

#### Solicited Local and Systemic Adverse Reactions

Overall, among participants who received a booster dose in a subset from Study C4591001 (Study 2), the median age was 42 years (range 19 through 55 years of age), 45.8% were male and 54.2% were female, 81.4% were White, 27.8% were Hispanic/Latino, 9.2% were Black or African American, 5.2% were Asian, and 0.7% were American Indian/Alaska Native.

**Table 14: Study 2 – Frequency and Percentages of Participants With Solicited Local Reactions, By Maximum Severity, Within 7 Days After the Booster Dose of COMIRNATY – Booster Dose Safety Population\***

Local Reaction	COMIRNATY <sup>†</sup> Booster Dose N <sup>a</sup> = 289 n <sup>b</sup> (%)
Redness <sup>c</sup>	
Any (>2 cm)	17 (5.9)
Severe	0
Swelling <sup>c</sup>	
Any (>2 cm)	23 (8.0)
Severe	1 (0.3)
Pain at the injection site <sup>d</sup>	
Any	240 (83.0)
Severe	1 (0.3)

Note: Reactions were collected in the electronic diary (e-diary) from Day 1 to Day 7 after the booster dose.

Note: No Grade 4 solicited local reactions were reported.

\*Participants in the safety analysis population who received the booster dose of COMIRNATY.

<sup>†</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. n = Number of participants with the specified reaction.

c. Mild: >2.0 to 5.0 cm; Moderate: >5.0 to 10.0 cm; Severe: >10.0 cm.

d. Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents daily activity.

In participants who received a booster dose the mean duration of pain at the injection site after the booster dose was 2.6 days (range 1 to 8 days), for redness 2.2 days (range 1 to 15 days), and for swelling 2.2 days (range 1 to 8 days).

**Table 15: Study 2 – Frequency and Percentages of Participants With Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After the Booster Dose of COMIRNATY – Booster Dose Safety Population\***

<b>Systemic Reaction</b>	<b>COMIRNATY<sup>‡</sup> Booster Dose N<sup>a</sup> = 289 n<sup>b</sup> (%)</b>
<b>Fever</b>	
≥38.0°C	25 (8.7)
≥38.0°C to 38.4°C	12 (4.2)
>38.4°C to 38.9°C	12 (4.2)
>38.9°C to 40.0°C	1 (0.3)
>40.0°C	0
<b>Fatigue<sup>c</sup></b>	
Any	184 (63.7)
Severe	13 (4.5)
<b>Headache<sup>c</sup></b>	
Any	140 (48.4)
Severe	3 (1.0)
<b>Chills<sup>c</sup></b>	
Any	84 (29.1)
Severe	3 (1.0)
<b>Vomiting<sup>d</sup></b>	
Any	5 (1.7)
Severe	0
<b>Diarrhea<sup>e</sup></b>	
Any	25 (8.7)
Severe	0
<b>New or worsened muscle pain<sup>c</sup></b>	
Any	113 (39.1)
Severe	4 (1.4)
<b>New or worsened joint pain<sup>c</sup></b>	
Any	73 (25.3)
Severe	1 (0.3)
<b>Use of antipyretic or pain medication<sup>f</sup></b>	135 (46.7)

Note: Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 to Day 7 after the booster dose.

Note: No Grade 4 solicited systemic reactions were reported.

\*Randomized participants in the safety analysis population who received the booster dose of COMIRNATY.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified event after the specified dose.

b. n = Number of participants with the specified reaction.

c. Mild: does not interfere with activity; Moderate: some interference with activity; Severe: prevents daily activity.

d. Mild: 1 to 2 times in 24 hours; Moderate: >2 times in 24 hours; Severe: requires intravenous hydration.

e. Mild: 2 to 3 loose stools in 24 hours; Moderate: 4 to 5 loose stools in 24 hours; Severe: 6 or more loose stools in 24 hours.

f. Severity was not collected for use of antipyretic or pain medication.

### Unsolicited Adverse Events

Overall, participants who received a booster dose in Study C4591031 (Study 4), had a median follow-up time of 2.5 months after the booster dose to the cut-off date (October 5, 2021).

In an analysis of all unsolicited adverse events reported following the booster dose of COMIRNATY, through 1 month after the booster dose, in participants 16 through 87 years of age (N = 5,055), adverse reactions included headache (5%), fever (4.8%), lymphadenopathy (2.8%), decreased appetite (0.2%), malaise (0.7%), nausea (0.9%), and pain in extremity (1.1%).

### Serious Adverse Events

Of the participants who received a booster dose of COMIRNATY or placebo (COMIRNATY = 5,055; placebo = 5,020) to the cut-off date (October 5, 2021), serious adverse events were reported by 0.3% of COMIRNATY recipients and 0.5% by placebo recipients. There were no notable patterns or numerical imbalances between treatment groups for specific categories of serious adverse events that would suggest a causal relationship to COMIRNATY. A 17-year-old male in Study 2 was diagnosed with myocarditis three days after receiving the booster dose (Dose 3). The participant was treated and recovered.

### Adolescents 12 to 15 Years of Age – Primary Series (Two Doses)

#### Solicited Adverse Reactions

Table 16 and Table 17 present the frequency and severity of solicited local and systemic reactions, respectively, within 7 days following each dose of COMIRNATY and placebo in adolescents 12 to 15 years of age included in the safety population who were monitored for reactogenicity with an electronic diary.

**Table 16: Study 2 – Frequency of Solicited Local Reactions Within 7 Days After Each Dose of COMIRNATY – Adolescents 12 to 15 Years of Age – Safety Population\***

Local Reaction	COMIRNATY <sup>†</sup> Dose 1 N <sup>a</sup> =1,127 n <sup>b</sup> (%)	Placebo Dose 1 N <sup>a</sup> =1,127 n <sup>b</sup> (%)	COMIRNATY <sup>†</sup> Dose 2 N <sup>a</sup> =1,097 n <sup>b</sup> (%)	Placebo Dose 2 N <sup>a</sup> =1,078 n <sup>b</sup> (%)
Redness				
Any (>2 cm)	65 (5.8)	12 (1.1)	55 (5.0)	10 (0.9)
Severe <sup>c</sup>	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling				
Any (>2 cm)	78 (6.9)	11 (1.0)	54 (4.9)	6 (0.6)
Severe <sup>c</sup>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pain at the injection site				
Any	971 (86.2)	263 (23.3)	866 (78.9)	193 (17.9)
Severe <sup>d</sup>	11 (1.0)	0 (0.0)	7 (0.6)	0 (0.0)
Any local reaction <sup>e</sup>	976 (86.6)	271 (24.0)	872 (79.5)	198 (18.4)

Note: Reactions were collected in the electronic diary (e-diary) from Day 1 to Day 7 after vaccination.

<sup>†</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. n = Number of participants with the specified reaction.

c. Severe: >10.0 cm.

d. Severe: prevents daily activity.

e. Any local reaction: any redness >2.0 cm, any swelling >2.0 cm, or any pain at the injection site

\* Randomized participants in the safety analysis population who received at least 1 dose of the study intervention.

**Table 17: Study 2 – Frequency of Solicited Systemic Reactions Within 7 Days After Each Dose of COMIRNATY – Adolescents 12 to 15 Years of Age – Safety Population\***

<b>Systemic Reaction</b>	<b>COMIRNATY<sup>‡</sup> Dose 1 N<sup>a</sup>=1,127 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1,127 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>‡</sup> Dose 2 N<sup>a</sup>=1,097 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1,078 n<sup>b</sup> (%)</b>
<b>Fever</b>				
≥38.0°C	114 (10.1)	12 (1.1)	215 (19.6)	7 (0.6)
>38.9°C	11 (1.0)	2 (0.2)	25 (2.3)	1 (0.1)
<b>Fatigue</b>				
Any	677 (60.1)	457 (40.6)	726 (66.2)	264 (24.5)
Severe <sup>c</sup>	15 (1.3)	8 (0.7)	26 (2.4)	4 (0.4)
<b>Headache</b>				
Any	623 (55.3)	396 (35.1)	708 (64.5)	263 (24.4)
Severe <sup>c</sup>	11 (1.0)	9 (0.8)	22 (2.0)	1 (0.1)
<b>Chills</b>				
Any	311 (27.6)	109 (9.7)	455 (41.5)	73 (6.8)
Severe <sup>c</sup>	5 (0.4)	2 (0.2)	20 (1.8)	0 (0.0)
<b>Vomiting</b>				
Any	31 (2.8)	10 (0.9)	29 (2.6)	12 (1.1)
Severe <sup>d</sup>	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Diarrhea</b>				
Any	90 (8.0)	82 (7.3)	65 (5.9)	43 (4.0)
Severe <sup>e</sup>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<b>New or worsened muscle pain</b>				
Any	272 (24.1)	148 (13.1)	355 (32.4)	90 (8.3)
Severe <sup>c</sup>	2 (0.2)	0 (0.0)	6 (0.5)	2 (0.2)
<b>New or worsened joint pain</b>				
Any	109 (9.7)	77 (6.8)	173 (15.8)	51 (4.7)
Severe <sup>c</sup>	1 (0.1)	0 (0.0)	4 (0.4)	0 (0.0)
Any systemic reactions <sup>f</sup>	877 (77.8)	636 (56.4)	904 (82.4)	439 (40.7)
Use of antipyretic or pain medication	413 (36.6)	111 (9.8)	557 (50.8)	95 (8.8)

Note: Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 to Day 7 after each dose.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified event after the specified dose.

b. n = Number of participants with the specified reaction.

c. Severe: prevents daily activity.

d. Severe: requires intravenous hydration.

e. Severe: 6 or more loose stools in 24 hours.

f. Any systemic reaction: any fever ≥38.0°C, any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any new or worsened joint pain

\* Randomized participants in the safety analysis population who received at least 1 dose of the study intervention.

### Unsolicited Adverse Events

In the analysis of Study 2 of all unsolicited adverse events reported following any dose, through 1 month after Dose 2, in adolescents 12 to 15 years of age (N=2260; 1,131 COMIRNATY group vs. 1,129 placebo group), those assessed as adverse reactions not already captured by solicited local and systemic reactions were lymphadenopathy (9 (0.8%) vs. 2 (0.2%)), and nausea (5 (0.4%) vs. 1 (0.1%)).

In analyses of all unsolicited adverse events in Study 2 from Dose 1 up to the participant unblinding date, 69.0% of study participants 12 through 15 years of age had at least 4 months of follow-up after Dose 2. Among participants 12 through 15 years of age who received at least one dose of study vaccine, 1,131 of whom received COMIRNATY and 1,129 of whom received placebo, unsolicited adverse events were reported by 95 (8.4%) participants in the COMIRNATY group and 113 (10.0%) participants in the placebo group.

Non-serious adverse events from Dose 1 through up to 30 days after Dose 2 in ongoing follow-up were reported by 5.8% of COMIRNATY recipients and by 5.8% of placebo recipients. From Dose 1 through 30 days after Dose 2, reports of lymphadenopathy plausibly related to the study intervention were imbalanced, with notably more cases in the COMIRNATY group (7) vs. the placebo group (1). In the analysis of blinded, placebo-controlled follow-up, there were no other notable patterns or numerical imbalances between treatment groups for specific categories of non-serious adverse events (including other neurologic or neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. In the analysis of unblinded follow-up, there were no notable patterns of specific categories of non-serious adverse events that would suggest a causal relationship to COMIRNATY.

### *Serious Adverse Events*

In Study 2, among participants 12 through 15 years of age who had received at least 1 dose of vaccine or placebo (COMIRNATY = 1,131; placebo = 1,129), serious adverse events from Dose 1 up to the participant unblinding date in ongoing follow-up were reported by 10 (0.9%) COMIRNATY recipients and 2 (0.2%) placebo recipients. In these analyses, 69.0% (786 COMIRNATY and 773 placebo) of study participants had at least 4 months of follow-up after Dose 2. In the analysis of blinded, placebo-controlled follow-up, there were no notable patterns between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. In the analysis of unblinded follow-up, there were no notable patterns of specific categories of serious adverse events that would suggest a causal relationship to COMIRNATY. In study 2, a 16-year-old male was diagnosed with myopericarditis 3 days after his 2nd dose. The participant was treated and recovered.

### **Coadministration of COMIRNATY with Seasonal Influenza Vaccine**

In Study 8 (C4591030), a Phase 3 study, participants 18 through 64 years of age who received COMIRNATY coadministered with standard dose unadjuvanted seasonal inactivated influenza vaccine (SIIV), quadrivalent followed 1 month later by placebo (n=564) were compared to participants who received SIIV quadrivalent with placebo followed 1 month later by COMIRNATY alone (n=564).

Reactogenicity events were reported more frequently by participants who received COMIRNATY coadministered with SIIV quadrivalent, compared to participants who received COMIRNATY or SIIV quadrivalent alone, but overall the reactogenicity events were mostly mild to moderate in severity. The most common adverse reactions reported in the coadministration group and after COMIRNATY alone

were injection site pain (86.2% and 84.4%, respectively), fatigue (64.0% and 50.8%, respectively) and headache (47.2% and 37.8%, respectively).

### 8.2.5 COMIRNATY (Original: 10 mcg)

#### Children 5 Years Through <12 Years of Age – Primary Series (Two Doses)

##### Solicited Adverse Reactions

Table 18 and Table 19 present the frequency and severity of solicited local and systemic reactions, respectively, within 7 days following each dose of COMIRNATY and placebo in children 5 years through <12 years of age included in the initial enrolment safety population who were monitored for reactogenicity with an electronic diary.

**Table 18: Study 3 – Frequency of Solicited Local Reactions Within 7 Days After Each Dose – Children 5 Years Through <12 Years of Age – Safety Population\***

Local Reaction	COMIRNATY <sup>‡</sup> Dose 1 N <sup>a</sup> =1,511 n <sup>c</sup> (%)	Placebo Dose 1 N <sup>a,b</sup> =748 n <sup>c</sup> (%)	COMIRNATY <sup>‡</sup> Dose 2 N <sup>a</sup> =1,501 n <sup>c</sup> (%)	Placebo Dose 2 N <sup>a,b</sup> =740 n <sup>c</sup> (%)
Redness <sup>d</sup>				
Any (≥0.5 cm)	222 (14.7)	43 (5.7)	278 (18.5)	40 (5.4)
Severe	0 (0.0)	0 (0.0)	3 (0.2)	0 (0.0)
Swelling <sup>d</sup>				
Any (≥0.5 cm)	158 (10.5)	20 (2.7)	229 (15.3)	20 (2.7)
Severe	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)
Pain at the injection site <sup>e</sup>				
Any	1,119 (74.1)	234 (31.3)	1,065 (71.0)	218 (29.5)
Severe	4 (0.3)	0 (0.0)	5 (0.3)	0 (0.0)

Note: Reactions were collected in the electronic diary (e-diary) from Day 1 to Day 7 after vaccination.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. The denominators (N) used in the percentage calculations for redness and swelling were 749 after Dose 1 and 741 after Dose 2 in the placebo group, due to an e-diary error.

c. n = Number of participants with the specified reaction.

d. Severe: >7.0 cm.

e. Severe: prevents daily activity.

\* Randomized participants who received at least 1 dose of the study intervention.

**Table 19: Study 3 – Frequency of Solicited Systemic Reactions Within 7 Days After Each Dose – Children 5 Years Through <12 Years of Age – Safety Population\***

<b>Systemic Reaction</b>	<b>COMIRNATY<sup>‡</sup> Dose 1 N<sup>a</sup>=1,511 n<sup>c</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a,b</sup>=748 n<sup>c</sup> (%)</b>	<b>COMIRNATY<sup>‡</sup> Dose 2 N<sup>a</sup>=1,501 n<sup>c</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a,b</sup>=740 n<sup>c</sup> (%)</b>
<b>Fever</b>				
≥38.0°C	38 (2.5)	10 (1.3)	98 (6.5)	9 (1.2)
>38.9°C	3 (0.2)	1 (0.1)	9 (0.6)	1 (0.1)
<b>Fatigue<sup>d</sup></b>				
Any	508 (33.6)	234 (31.3)	592 (39.4)	180 (24.3)
Severe	4 (0.3)	1 (0.1)	11 (0.7)	1 (0.1)
<b>Headache<sup>d</sup></b>				
Any	339 (22.4)	180 (24.1)	420 (28.0)	138 (18.6)
Severe	2 (0.1)	4 (0.5)	3 (0.2)	0 (0.0)
<b>Chills<sup>d</sup></b>				
Any	70 (4.6)	35 (4.7)	147 (9.8)	32 (4.3)
Severe	0 (0.0)	0 (0.0)	2 (0.1)	1 (0.1)
<b>Vomiting<sup>e</sup></b>				
Any	33 (2.2)	11 (1.5)	28 (1.9)	6 (0.8)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Diarrhea<sup>f</sup></b>				
Any	89 (5.9)	31 (4.1)	79 (5.3)	35 (4.7)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<b>New or worsened muscle pain<sup>d</sup></b>				
Any	137 (9.1)	51 (6.8)	175 (11.7)	55 (7.4)
Severe	1 (0.1)	0 (0.0)	1 (0.1)	0 (0.0)
<b>New or worsened joint pain<sup>d</sup></b>				
Any	50 (3.3)	41 (5.5)	78 (5.2)	27 (3.6)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Use of antipyretic or pain medication<sup>g</sup></b>	217 (14.4)	62 (8.3)	296 (19.7)	60 (8.1)

Note: Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 to Day 7 after each dose.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified event after the specified dose.

b. The denominators (N) used in the percentage calculations for fever and use of antipyretic or pain medication were 749 after Dose 1 and 741 after Dose 2 in the placebo group, due to an e-diary error.

c. n = Number of participants with the specified reaction.

d. Severe: prevents daily activity.

e. Severe: requires intravenous hydration.

f. Severe: 6 or more loose stools in 24 hours.

g. Severity was not collected for use of antipyretic or pain medication.

\* Randomized participants who received at least 1 dose of the study intervention.

### Unsolicited Adverse Events

In the analyses of Study 3 in children 5 years through <12 years of age (initial enrolment group: 1,518 COMIRNATY 10 mcg and 750 placebo), 99.5% of participants had at least 30 days and 95.7% of participants had at least 3 months follow-up after Dose 2.

Serious adverse events from Dose 1 through up to 30 days after Dose 2 in ongoing follow-up in the initial enrolment group were reported by 1 participant (0.1%) in each group after receiving the vaccine or placebo through the data cut-off date. No serious adverse events were reported that were considered related to vaccination.

Non-serious adverse events from Dose 1 through up to 30 days after Dose 2 in ongoing follow-up in the initial enrolment group were reported by 10.9% of COMIRNATY 10 mcg recipients and by 9.1% of placebo recipients. Lymphadenopathy was reported in 13 (0.9%) participants in the COMIRNATY 10 mcg group vs. 1 (0.1%) in the placebo group. All cases were considered to be mild, with a median onset of 3 days after Dose 1, and 2 days after Dose 2 in the vaccine group. The median duration was 3.5 days (ranged from 1 to 14 days) in the vaccine group. Skin and subcutaneous tissue disorders (including skin rash, dermatitis, eczema and urticaria) were reported in 17 (1.1%) participants in the vaccine group and 5 (0.7%) participants in the placebo group. Most of the events began from 3-11 days after the second dose and were characterized as mild and self-limited. There were no other notable patterns between treatment groups for specific categories of non-serious adverse events that would suggest a causal relationship to COMIRNATY. There were no reports of myocarditis/pericarditis or anaphylaxis by the study cut-off date.

### **Children 5 Years Through <12 Years of Age – After Booster Dose**

A subset of Phase 2/3 participants 5 years through <12 years of age received a booster dose of COMIRNATY at least 5 months after completing the primary series (range 5 to 9 months, 86.8% of participants received the booster dose at least 8 months after Dose 2). Those participants vaccinated prior to February 22, 2022 provided the safety database (n=401), and had a median safety follow-up of 1.3 months from vaccination through the data cut-off date of March 22, 2022.

The median age of these 401 participants was 8.0 years (range 5 years through <12 years of age), 52.4% were male and 47.6% were female, 70.1% were White, 7.2% were Black or African American, 22.9% were Hispanic/Latino, 7.7% were Asian, and 2.0% were American Indian/Alaska Native.

### **Solicited Local and Systemic Adverse Reactions**

Table 20 and Table 21 present the frequency and severity of reported solicited local and systemic reactions, respectively, within 7 days of a booster dose of COMIRNATY for Phase 2/3 participants 5 years through <12 years of age.

In participants who received a booster dose, the mean duration of pain at the injection site after the booster dose was 2.4 days (range 1 to 35 days), for redness 2.3 days (range 1 to 12 days), and for swelling 2.3 days (range 1 to 9 days).



**Table 20: Study 3 – Frequency and Percentages of Participants With Solicited Local Reactions, By Maximum Severity, Within 7 Days After the Booster Dose of COMIRNATY– Children 5 Years through <12 Years of Age – Safety Population\***

Local Reaction	COMIRNATY <sup>‡</sup> Booster N <sup>a</sup> =371 n <sup>b</sup> (%)
Redness <sup>c</sup>	
Any (≥0.5 cm)	58 (15.6)
Severe	1 (0.3)
Swelling <sup>c</sup>	
Any (≥0.5 cm)	61 (16.4)
Severe	0
Pain at the injection site <sup>d</sup>	
Any	274 (73.9)
Severe	2 (0.5)

\* Randomized participants who received at least 1 dose of the study intervention.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

Note: Reactions were collected in the e-diary and unscheduled clinical assessments from Day 1 through Day 7 after vaccination.

a. N = number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. n = Number of participants with the specified characteristic.

c. Mild: ≥0.5 to 2.0 cm; moderate: >2.0 to 7.0 cm; severe: >7.0 cm.

d. Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity.

**Table 21: Study 3 – Frequency and Percentages of Participants With Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After the Booster Dose of COMIRNATY– Children 5 Years through <12 Years of Age – Safety Population\***

Systemic Reaction	COMIRNATY <sup>‡</sup> Booster N <sup>a</sup> =371 n <sup>b</sup> (%)
Fever	
≥38.0°C	25 (6.7)
>38.9°C	3 (0.8)
Fatigue <sup>c</sup>	
Any	169 (45.6)
Severe	7 (1.9)
Headache <sup>c</sup>	
Any	126 (34.0)
Severe	0
Chills <sup>c</sup>	
Any	39 (10.5)
Severe	1 (0.3)
Vomiting <sup>d</sup>	
Any	9 (2.4)
Severe	0
Diarrhea <sup>e</sup>	
Any	18 (4.9)
Severe	1 (0.3)
New or worsened muscle pain <sup>c</sup>	
Any	68 (18.3)
Severe	0
New or worsened joint pain <sup>c</sup>	
Any	25 (6.7)
Severe	0
Use of antipyretic or pain medication <sup>f</sup>	114 (30.7)

\* Randomized participants who received at least 1 dose of the study intervention.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

Note: Events and use of antipyretic or pain medication were collected in the e-diary and unscheduled clinical assessments from Day 1 through Day 7 after vaccination.

a. N = number of participants reporting at least 1 yes or no response for the specified event after the specified dose.

b. n = Number of participants with the specified characteristic.

c. Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity.

d. Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration.

e. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours.

f. Severity was not collected for use of antipyretic or pain medication.

### Unsolicited Adverse Events

Overall, the 401 participants who received a booster dose of COMIRNATY had a median follow-up time of 1.3 months after the booster dose through the cut-off date.

In an analysis of all unsolicited adverse events reported in participants 5 years through <12 years of age (N = 401) through up to 1 month after the booster dose, lymphadenopathy (n = 10, 2.5%) was an adverse reaction not already captured by solicited local and systemic reactions.

### Serious Adverse Events

No serious adverse events were reported after the booster dose of COMIRNATY through the cut-off date.

## 8.2.6 COMIRNATY (Original: 3 mcg)

### Children 2 Through <5 Years of Age – Primary Series (Three Doses)

#### Solicited Adverse Reactions

Table 22 and Table 23 present the frequency of solicited local and systemic reactions, respectively, within 7 days following each dose of COMIRNATY and placebo in children 2 through <5 years of age who were monitored for reactogenicity with an electronic diary.

**Table 22: Study 3 – Frequency of Solicited Local Reactions Within 7 Days After Each Dose – Children 2 Through <5 Years of Age – Safety Population\***

Local Reaction	COMIRNATY <sup>†</sup> Dose 1 N <sup>a</sup> =1,814 to 1,825 n <sup>b</sup> (%)	Placebo Dose 1 N <sup>a</sup> =905 to 909 n <sup>b</sup> (%)	COMIRNATY <sup>†</sup> Dose 2 N <sup>a</sup> =1,772 to 1,779 n <sup>b</sup> (%)	Placebo Dose 2 N <sup>a</sup> =877 to 878 n <sup>b</sup> (%)	COMIRNATY <sup>†</sup> Dose 3 N <sup>a</sup> =547 to 552 n <sup>b</sup> (%)	Placebo Dose 3 N <sup>a</sup> =262 n <sup>b</sup> (%)
Redness						
Any (≥0.5 cm)	160 (8.8)	77 (8.5)	202 (11.4)	50 (5.7)	60 (10.9)	9 (3.4)
Severe <sup>c</sup>	1 (0.1)	1 (0.1)	1 (0.1)	0	0	0
Swelling						
Any (≥0.5 cm)	67 (3.7)	26 (2.9)	102 (5.7)	18 (2.1)	17 (3.1)	3 (1.1)
Severe <sup>c</sup>	0	0	0	0	0	0
Pain at the injection site						
Any	559 (30.8)	186 (20.6)	550 (31.0)	178 (20.3)	146 (26.7)	35 (13.4)
Severe <sup>d</sup>	0	1 (0.1)	0	1 (0.1)	0	0

\* Randomized participants who received at least 1 dose of the study intervention.

† COMIRNATY 3 mcg. (vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain [Original]).

Note: Reactions were collected in an electronic diary (e-diary) from Day 1 to Day 7 after vaccination.

- N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.
- n = Number of participants with the specified reaction.
- Severe: >7.0 cm.
- Severe: prevents daily activity.

**Table 23: Study 3 – Frequency of Solicited Systemic Reactions Within 7 Days After Each Dose – Children 2 Through <5 Years of Age – Safety Population\***

<b>Systemic Reaction</b>	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=1,813 to 1,824 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=905 to 909 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1,772 to 1,779 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=877 to 878 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 3 N<sup>a</sup>=547 to 552 n<sup>b</sup> (%)</b>	<b>Placebo Dose 3 N<sup>a</sup>=262 n<sup>b</sup> (%)</b>
<b>Fever</b>						
≥38.0°C	95 (5.2)	48 (5.3)	88 (4.9)	46 (5.2)	28 (5.1)	11 (4.2)
>38.9°C	14 (0.8)	8 (0.9)	21 (1.2)	8 (0.9)	4 (0.7)	3 (1.1)
<b>Fatigue</b>						
Any	539 (29.7)	277 (30.6)	456 (25.7)	201 (22.9)	134 (24.5)	57 (21.8)
Severe <sup>c</sup>	6 (0.3)	5 (0.6)	8 (0.5)	3 (0.3)	2 (0.4)	0
<b>Headache</b>						
Any	81 (4.5)	44 (4.9)	81 (4.6)	36 (4.1)	27 (4.9)	11 (4.2)
Severe <sup>c</sup>	0	1 (0.1)	0	1 (0.1)	0	0
<b>Chills</b>						
Any	41 (2.3)	22 (2.4)	53 (3.0)	23 (2.6)	18 (3.3)	7 (2.7)
Severe <sup>c</sup>	3 (0.2)	0	0	0	1 (0.2)	0
<b>Vomiting</b>						
Any	54 (3.0)	24 (2.7)	61 (3.4)	29 (3.3)	9 (1.6)	10 (3.8)
Severe <sup>d</sup>	0	0	0	0	0	0
<b>Diarrhea</b>						
Any	139 (7.7)	72 (8.0)	118 (6.7)	64 (7.3)	28 (5.1)	13 (5.0)
Severe <sup>e</sup>	0	0	1 (0.1)	0	0	0
<b>New or worsened muscle pain</b>						
Any	43 (2.4)	15 (1.7)	46 (2.6)	21 (2.4)	11 (2.0)	4 (1.5)
Severe <sup>c</sup>	1 (0.1)	0	0	0	0	0
<b>New or worsened joint pain</b>						
Any	14 (0.8)	18 (2.0)	24 (1.4)	9 (1.0)	7 (1.3)	2 (0.8)
Severe <sup>c</sup>	0	0	0	0	1 (0.2)	0
<b>Use of antipyretic or pain medication<sup>f</sup></b>						
	197 (10.8)	83 (9.1)	177 (9.9)	74 (8.4)	47 (8.5)	18 (6.9)

\* Randomized participants who received at least 1 dose of the study intervention.

<sup>†</sup> COMIRNATY 3 mcg (vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain [Original]).

Note: Events and use of antipyretic or pain medication were collected in an electronic diary (e-diary) from Day 1 to Day 7 after each dose.

- a. N = Number of participants reporting at least 1 yes or no response for the specified event after the specified dose.
- b. n = Number of participants with the specified reaction.
- c. Severe: prevents daily activity.
- d. Severe: requires intravenous hydration.
- e. Severe: 6 or more loose stools in 24 hours.
- f. Severity was not collected for use of antipyretic or pain medication.

#### Unsolicited Adverse Events

In the analyses of Study 3 in participants 2 through <5 years of age (606 COMIRNATY; 280 placebo), 76.6% of participants had at least 30 days of follow-up after Dose 3.

Serious adverse events from Dose 1 through 1 month after Dose 3, with an overall median of 1.4 months follow-up after Dose 3, were reported by 0.7% of COMIRNATY recipients and by 0.9% of placebo recipients. One serious adverse event of fever (maximum temperature 40.3°C) on Day 3 after Dose 2 in a 4-year-old was considered possibly related to vaccination.

Non-serious adverse events from Dose 1 through up to 30 days after Dose 3, in ongoing follow-up were reported by 18.5% of COMIRNATY recipients and by 18.5% of placebo recipients.

From Dose 1 through 30 days after Dose 3, lymphadenopathy was reported in 1 (0.1%) of COMIRNATY recipients vs. 0 (0.0%) of placebo recipients. There were no other notable patterns between treatment groups for specific categories of non-serious adverse events that would suggest a causal relationship to COMIRNATY.

### **Children 6 Months Through <2 Years of Age – Primary Series (Three Doses)**

#### **Solicited Adverse Reactions**

Table 24 and Table 25 present the frequency of solicited local and systemic reactions, respectively, within 7 days following each dose of COMIRNATY and placebo in children 6 months through <2 years of age who were monitored for reactogenicity with an electronic diary.

**Table 24: Study 3 – Frequency of Solicited Local Reactions Within 7 Days After Each Dose – Children 6 Months Through <2 Years of Age – Safety Population\***

<b>Local Reaction</b>	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=1,159 to 1,173 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=591 to 595 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1,137 to 1,147 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=590 to 591 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 3 N<sup>a</sup>=362 to 365 n<sup>b</sup> (%)</b>	<b>Placebo Dose 3 N<sup>a</sup>=170 n<sup>b</sup> (%)</b>
<b>Redness</b>						
Any (≥0.5 cm)	124 (10.6)	44 (7.4)	107 (9.3)	39 (6.6)	26 (7.1)	9 (5.3)
Severe <sup>c</sup>	0	0	0	0	1 (0.3)	0
<b>Swelling</b>						
Any (≥0.5 cm)	46 (3.9)	15 (2.5)	45 (3.9)	9 (1.5)	10 (2.7)	3 (1.8)
Severe <sup>c</sup>	0	0	0	0	0	0
<b>Tenderness at the injection site</b>						
Any	192 (16.6)	66 (11.2)	171 (15.0)	50 (8.5)	58 (16.0)	20 (11.8)
Severe <sup>d</sup>	0	0	1 (0.1)	0	0	0

\* Randomized participants who received at least 1 dose of the study intervention.

<sup>†</sup> COMIRNATY 3 mcg. (vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain [Original]).

Note: Reactions were collected in an electronic diary (e-diary) from Day 1 to Day 7 after vaccination.

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. n = Number of participants with the specified reaction.

c. Severe: >7.0 cm.

d. Severe: causes limitation of limb movement.

**Table 25: Study 3 – Frequency of Solicited Systemic Reactions Within 7 Days After Each Dose – Children 6 Months Through <2 Years of Age – Safety Population\***

<b>Systemic Reaction</b>	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=1,159 to 1,173 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=591 to 595 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1,137 to 1,147 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=590 to 591 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 3 N<sup>a</sup>=362 to 365 n<sup>b</sup> (%)</b>	<b>Placebo Dose 3 N<sup>a</sup>=170 n<sup>b</sup> (%)</b>
<b>Fever</b>						
≥38.0°C	85 (7.2)	43 (7.2)	85 (7.4)	36 (6.1)	25 (6.8)	10 (5.9)
>38.9°C to 40.0°C	20 (1.7)	7 (1.2)	24 (2.1)	7 (1.2)	6 (1.6)	1 (0.6)
<b>Decreased appetite</b>						
Any	257 (22.2)	125 (21.2)	252 (22.2)	106 (18.0)	73 (20.2)	23 (13.5)
Severe <sup>c</sup>	3 (0.3)	1 (0.2)	4 (0.4)	1 (0.2)	4 (1.1)	0
<b>Drowsiness</b>						
Any	313 (27.0)	173 (29.3)	271 (23.8)	125 (21.2)	72 (19.9)	22 (12.9)
Severe <sup>d</sup>	2 (0.2)	2 (0.3)	4 (0.4)	1 (0.2)	1 (0.3)	1 (0.6)
<b>Irritability</b>						
Any	593 (51.2)	279 (47.2)	539 (47.4)	240 (40.7)	158 (43.6)	64 (37.6)
Severe <sup>e</sup>	7 (0.6)	0	7 (0.6)	5 (0.8)	1 (0.3)	0
Use of antipyretic or pain medication <sup>f</sup>	281 (24.0)	117 (19.7)	243 (21.2)	111 (18.8)	70 (19.2)	28 (16.5)

\* Randomized participants who received at least 1 dose of the study intervention.

<sup>†</sup> COMIRNATY 3 mcg (vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain [Original]).

Note: Events and use of antipyretic or pain medication were collected in an electronic diary (e-diary) from Day 1 to Day 7 after each dose.

- a. N = Number of participants reporting at least 1 yes or no response for the specified event after the specified dose.
- b. n = Number of participants with the specified reaction.
- c. Severe: refusal to feed.
- d. Severe: disabling; not interested in usual daily activity.
- e. Severe: inconsolable; crying cannot be comforted.
- f. Severity was not collected for use of antipyretic or pain medication.

### Unsolicited Adverse Events

In the analyses of Study 3 in participants 6 months through 2 years of age (386 COMIRNATY; 184 placebo), 83.7% of participants had at least 30 days of follow-up after Dose 3.

Serious adverse events from Dose 1 through 1 month after Dose 3, with an overall median of 1.3 months follow-up after Dose 3, were reported by 1.4% of COMIRNATY recipients and by 2.3% of placebo recipients. No serious adverse events were reported that were considered related to vaccination.

Non-serious adverse events from Dose 1 through up to 1 month after Dose 3, in ongoing follow-up were reported by 29.1% of COMIRNATY recipients and by 26.3% of placebo recipients.

From Dose 1 through 30 days after Dose 3, lymphadenopathy was reported in 2 (0.2%) of COMIRNATY recipients vs. 0 (0%) of placebo recipients. There were no other notable patterns between treatment groups for specific categories of non-serious adverse events that would suggest a causal relationship to COMIRNATY.

## 8.5 Post-Market Adverse Reactions

The following adverse reactions have been identified during post authorization use of COMIRNATY.

Cardiac disorders: myocarditis and/or pericarditis (see [7 WARNING AND PRECAUTIONS](#))

Immune system disorders: severe allergic reactions, including anaphylaxis

Musculoskeletal and connective tissue disorders: pain in extremity (arm)

Nervous system disorders: Facial paralysis / Bell's Palsy, hypoesthesia, paresthesia, dizziness

Skin and subcutaneous tissue disorders and other hypersensitivity reactions: skin rash, pruritus, urticaria, angioedema, erythema multiforme

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. They are included because: a) they represent reactions that are known to occur following immunizations generally; b) they are potentially serious; or c) on the basis of their frequency of reporting.

## 9 DRUG INTERACTIONS

### Adults 18 Through 64 Years of Age

COMIRNATY may be administered concomitantly with seasonal inactivated influenza vaccine. The effectiveness of the coadministration is inferred from a study which evaluated non-inferiority of immune response to coadministration of COMIRNATY (original) with an unadjuvanted seasonal inactivated influenza vaccine as compared to either vaccine alone. (see [14.2.3.3 Coadministration of COMIRNATY with Influenza Vaccine](#)).

Different injectable vaccines should be given at different sites.

Do not mix COMIRNATY with other vaccines/products in the same syringe.

## 10 CLINICAL PHARMACOLOGY

### 10.1 Mechanism of Action

The nucleoside-modified messenger RNA in COMIRNATY encodes for the viral spike (S) protein of SARS-CoV-2 Omicron variant lineage KP.2. The mRNA is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19 disease.

## 11 STORAGE, STABILITY AND DISPOSAL

Regardless of presentation, during storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

Regardless of storage condition, the vaccine should not be used after the expiration date printed on the vials, prefilled syringes and cartons.

Do not refreeze thawed vials.

### **Storage Prior to Use**

#### ***Single Dose or Multiple Dose Vials***

Cartons of COMIRNATY single dose or multiple dose vials may arrive frozen at ultra-cold conditions in thermal containers with dry ice.

Once received, frozen single dose or multiple dose vials may be immediately transferred to the refrigerator at 2°C to 8°C (35°F to 46°F), thawed and stored for a single period of up to 10 weeks within the shelf-life. The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer. Thaw times for 10-vial packs are noted below:

<b>Vial Cap and Vial Label Colour</b>	<b>Time That May Be Required for a 10-Vial Pack to Thaw (at 2°C to 8°C)</b>
Dark Gray Dark Blue	6 hours
Light Gray Light Blue Yellow	2 hours

Alternatively, frozen single dose or multiple dose vials may be stored in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76°F). Do not store vials at -25°C to -15°C (-13°F to 5°F). Once vials are thawed they should not be refrozen.

Cartons of COMIRNATY single dose or multiple dose vials may also arrive at 2°C to 8°C (35°F to 46°F). If received at 2°C to 8°C, they should be stored at 2°C to 8°C. Check that the carton has been updated to reflect the 10-week refrigerated expiry date.

#### ***Prefilled Syringes***

COMIRNATY prefilled syringes may be stored at 2°C to 8°C (35°F to 46°F) until the expiration date printed on the carton and syringe labels. DO NOT FREEZE.

### **Storage During Use**

#### ***Single Dose or Multiple Dose Vials***

If not previously thawed at 2°C to 8°C (35°F to 46°F), allow single dose or multiple dose vials to thaw at room temperature [up to 25°C (77°F)] for 30 minutes.

Thawed single dose or multiple dose vials may be stored at room temperature up to 25°C (77°F) for a total of 12 hours prior to the first puncture.

DO NOT DILUTE PRIOR TO USE.



After first puncture, the single dose or multiple dose vial should be stored at 2°C to 25°C (35°F to 77°F). Vials should be discarded 12 hours after first puncture.

Thawed single dose or multiple dose vials can be handled in room light conditions.

### ***Prefilled Syringes***

After removing the tip cap and attaching an appropriate needle, the prefilled syringes should be used immediately. If it cannot be used immediately, it must be used within 4 hours.

### **Transportation**

#### ***Single Dose or Multiple Dose Vials***

If local redistribution is needed, full cartons containing unpunctured single dose or multiple dose vials may be transported at -90°C to -60°C (-130°F to -76°F); full cartons or individual unpunctured single dose or multiple dose vials may also be transported at 2°C to 8°C (35°F to 46°F).

### ***Prefilled Syringes***

Prefilled syringes may be transported at 2°C to 8°C (35°F to 46°F) and should never be frozen.

## **12 SPECIAL HANDLING INSTRUCTIONS**

COMIRNATY should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared suspension.

COMIRNATY single dose and multiple dose vials contain a frozen suspension that does not contain preservative and must be thawed and may require dilution prior to administration.

Careful attention should be paid to the vial cap colour and label border and information on the label, and the appropriate corresponding instructions must be followed. For important information on handling and preparation for administration, please refer to [11 STORAGE, STABILITY AND DISPOSAL](#) and [4 DOSAGE AND ADMINISTRATION](#).

## PART II: SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION

#### Drug Substance:

Proper name: COVID-19 mRNA Vaccine

Medicinal ingredient name:

mRNA encoding SARS-CoV-2 spike protein, 5' [m<sub>2</sub><sup>7,3'-O</sup>Gppp(m<sub>1</sub><sup>2'-O</sup>)ApG] cap, 110-nucleotide 3' poly(A) tail with a 10-nucleotide linker sequence

#### Product Characteristics:

COMIRNATY (COVID-19 mRNA Vaccine) contains highly purified single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free *in vitro* transcription from the corresponding DNA template encoding the viral spike (S) protein of the SARS-CoV-2 Omicron variant KP.2.

This vaccine is a white to off-white suspension.

For 12 Years and Older: **DO NOT DILUTE** (Single Dose Vials with Light Gray Cap/Label Border)

One single dose vial contains 1 dose of 0.3 mL. One dose (0.3 mL) contains 30 micrograms of COVID-19 mRNA, embedded in lipid nanoparticles.

For 12 Years and Older: **DO NOT DILUTE** (Multiple Dose Vials with Dark Gray Cap/Label Border)

One multiple dose vial (2.25 mL) contains 6 doses of 0.3 mL. One dose (0.3 mL) contains 30 micrograms of COVID-19 mRNA, embedded in lipid nanoparticles.

For Age 5 Years Through 11 Years: **DO NOT DILUTE** (Single Dose Vials with Light Blue Cap/Label Border)

One single dose vial contains 1 dose of 0.3 mL. One dose (0.3 mL) contains 10 micrograms of COVID-19 mRNA, embedded in lipid nanoparticles.

For Age 5 Years Through 11 Years: **DO NOT DILUTE** (Multiple Dose Vials with Dark Blue Cap/Label Border)

One multiple dose vial (2.25 mL) contains 6 doses of 0.3 mL. One dose (0.3 mL) contains 10 micrograms of COVID-19 mRNA, embedded in lipid nanoparticles.

For Age 6 Months Through 4 Years: **DILUTE PRIOR TO USE** (Multiple Dose Vials with Yellow Cap/Label Border)

One multiple dose vial (0.48 mL) contains 3 doses of 0.3 mL **after dilution**. One dose (0.3 mL) contains 3 micrograms of COVID-19 mRNA Vaccine, embedded in lipid nanoparticles.

## 14 CLINICAL TRIALS

### 14.1 Trial Design and Study Demographics

The safety and effectiveness of COMIRNATY for individuals 6 months of age and older are inferred from studies which evaluated the primary series and booster vaccination with COMIRNATY (Original) and supported by studies which evaluated a booster dose of COMIRNATY Original & Omicron BA.4/BA.5 in individuals 6 months of age and older.

#### 14.1.1 COMIRNATY Original & Omicron BA.4/BA.5 (15/15mcg)

*Relative vaccine immunogenicity in participants greater than 12 years of age – after a second booster dose of COMIRNATY bivalent vaccine*

Study C4591044 (Study 5) is an ongoing Phase 2/3 study to evaluate the safety, tolerability, and immunogenicity of new bivalent vaccines including COMIRNATY Original & Omicron BA.4/BA.5. A subset of 107 Study 5 Phase 2/3 participants 12 through 17 years of age, 313 participants 18 through 55 years of age and 306 participants 56 years of age and older previously vaccinated with a 2-dose primary series and 1 booster dose of COMIRNATY (original vaccine), went on to receive a second booster dose with COMIRNATY Original & Omicron BA.4/BA.5 (15/15 mcg, bivalent vaccine). Participants received a second booster dose 11.1 months (median time; range 5.4 to 16.9 months) after receiving the first booster dose and had a median follow up time of 1.5 months up to a data cut-off date of 31 October 2022. The median age was 48.0 years, 42.7% were male, 57.3% were female, 80.6% were White, 11.4% were Hispanic/Latino, 5.9% were Asian, and 11.4% were Black or African American.

#### 14.1.2 COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg)

*Relative vaccine Immunogenicity in children 6 months through <5 years of age – after the booster (fourth dose)*

Study C4591048 (Study 6) is a Phase 1/2/3 master study investigating the safety, tolerability, and immunogenicity of COMIRNATY Original & Omicron BA.4/BA.5 bivalent vaccine. In Study 6, a subset of 60 participants 6 months through <5 years of age received a booster dose (fourth dose) of COMIRNATY Original & Omicron BA.4/BA.5 (1.5 mcg/1.5 mcg) after receiving 3 prior doses of COMIRNATY (3 mcg), with their last dose 60 to 240 days prior to enrollment. The evaluable immunogenicity population (with or without evidence of infection up to 1month post-Dose 4) included 58 participants ≥6 months through <5 years of age (23 were ≥6 months through <2 years of age and 35 were 2 through <5 years of age). A total of 50.0% of participants were male. Most participants were White (58.6%), with 5.2% Black or African American participants, 15.5% Asian participants, and 20.7% multiracial participants. There were 25.9% Hispanic/Latino participants. Median age at the fourth dose was 19.0 months for the ≥6 months through <2 years of age group and 2.0 years for the 2 through <5 years of age group. Overall, 8.6% of participants reported comorbidities. A total of 27.6% of participants had evidence of prior SARS-CoV-2 infection at the time of Dose 4 (“baseline positive”).

#### 14.1.3 COMIRNATY (Original: 30 mcg)

The safety and efficacy of COMIRNATY were evaluated in Study 2, a multicenter, multinational, Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection and efficacy study in participants 12 years of age and older. Randomization was stratified by age: 12 through 15 years of age, 16 through 55 years of age, or 56 years of age and older, with a minimum of 40% of participants in the ≥56 year stratum. The study excluded participants who were

immunocompromised and those who had previous clinical or microbiological diagnosis of COVID-19. Participants with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, were included as were participants with known stable infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).

In the Phase 2/3 portion of Study 2, based on data accrued through November 14, 2020, approximately 44,000 participants 12 years of age and older were randomized equally and received 2 doses of COMIRNATY or placebo. The efficacy analyses included participants that received their second vaccination within 19 to 42 days after their first vaccination. The majority (93.1%) of vaccine recipients received the second dose 19 days to 23 days after Dose 1. Participants are planned to be followed for up to 24 months, for assessments of safety and efficacy against COVID-19.

The population for the analysis of the primary efficacy endpoint included 36,621 participants 12 years of age and older (18,242 in the COMIRNATY group and 18,379 in the placebo group) who did not have evidence of prior infection with SARS-CoV-2 through 7 days after the second dose. Table 26 presents the specific demographic characteristics in the studied population.

**Table 26: Demographics (Population for the Primary Efficacy Endpoint)<sup>a</sup> (Data Accrued Through November 14, 2020)**

	<b>COMIRNATY<sup>†</sup></b> <b>(N=18,242)</b> <b>n (%)</b>	<b>Placebo</b> <b>(N=18,379)</b> <b>n (%)</b>
<b>Sex</b>		
Male	9,318 (51.1)	9,225 (50.2)
Female	8,924 (48.9)	9,154 (49.8)
<b>Age (years)</b>		
Mean (SD)	50.6 (15.70)	50.4 (15.81)
Median	52.0	52.0
Min, max	(12, 89)	(12, 91)
<b>Age group</b>		
12 to 15 years	46 (0.3)	42 (0.2)
16 to 64 years	14,216 (77.9)	14,299 (77.8)
65 to 74 years	3,176 (17.4)	3,226 (17.6)
≥75 years	804 (4.4)	812 (4.4)
<b>Race</b>		
White	15,110 (82.8)	15,301 (83.3)
Black or African American	1,617 (8.9)	1,617 (8.8)
American Indian or Alaska Native	118 (0.6)	106 (0.6)
Asian	815 (4.5)	810 (4.4)
Native Hawaiian or other Pacific Islander	48 (0.3)	29 (0.2)
Other <sup>b</sup>	534 (2.9)	516 (2.8)
<b>Ethnicity</b>		
Hispanic or Latino	4,886 (26.8)	4,857 (26.4)
Not Hispanic or Latino	13,253 (72.7)	13,412 (73.0)
Not reported	103 (0.6)	110 (0.6)
<b>Comorbidities<sup>c</sup></b>		

**Table 26: Demographics (Population for the Primary Efficacy Endpoint)<sup>a</sup> (Data Accrued Through November 14, 2020)**

	<b>COMIRNATY<sup>†</sup></b> <b>(N=18,242)</b> <b>n (%)</b>	<b>Placebo</b> <b>(N=18,379)</b> <b>n (%)</b>
Yes	8,432 (46.2)	8,450 (46.0)
No	9,810 (53.8)	9,929 (54.0)

<sup>†</sup>Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. All eligible randomized participants who receive all vaccination(s) as randomized within the predefined window, have no other important protocol deviations as determined by the clinician, and have no evidence of SARS-CoV-2 infection prior to 7 days after Dose 2.

b. Includes multiracial and not reported.

c. Number of participants who have 1 or more comorbidities that increase the risk of severe COVID-19 disease.

- Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic pulmonary fibrosis, and cystic fibrosis) or moderate to severe asthma
- Significant cardiac disease (e.g., heart failure, coronary artery disease, congenital heart disease, cardiomyopathies, and pulmonary hypertension)
- Obesity (body mass index  $\geq 30$  kg/m<sup>2</sup>)
- Diabetes (Type 1, Type 2, or gestational)
- Liver disease
- Human Immunodeficiency Virus (HIV) infection (not included in the efficacy evaluation)

To assess boostability, a subset of Study 2 participants were enrolled in selected sites, and 306 participants aged 18 to 55 years were re-randomized to receive a booster dose approximately 6 months after completion of the two-dose regimen (median interval between dose 2 and booster dose – 6.8 months; range 4.8 to 8.0 months). The median age at the time of booster vaccination was 42.0 years, and 46.3% of participants were male.

In Study 4, a placebo-controlled booster study, 5,081 participants 16 years of age and older were recruited from Study 2 to receive a booster dose of COMIRNATY at least 6 months after the second dose. The median age at the time of booster vaccination was 53 years, and 49% of the participants were male.

#### **14.1.4 COMIRNATY (Original: 10 mcg)**

##### **Participants 5 Through <12 Years of Age**

Study 3 is a Phase 1/2/3 study comprised of an open-label vaccine dose finding portion (Phase 1) and a multicentre, multinational, randomized, saline placebo-controlled, observer-blind immunogenicity and efficacy portion (Phase 2/3) that has enrolled participants 6 months to <12 years of age.

**Participants 5 Through <12 Years of Age:** Demographic characteristics in Study 3 were generally similar with regard to age, gender, race, and ethnicity among participants 5 years through <12 years of age who received COMIRNATY 10 mcg and those who received placebo. Among the 1,518 participants (initial enrolment group) 5 years through <12 years of age who received at least 1 dose of COMIRNATY 10 mcg, 52.6% were male and 47.4% were female, 79.3% were White, 5.9% were Black or African American, 21.0% were Hispanic/Latino, 5.9% were Asian, and 0.8% were American Indian/Alaska Native.

A descriptive efficacy analysis of Study 3 has been performed in 1,968 children 5 years through <12 years of age without evidence of infection prior to 7 days after Dose 2. This analysis evaluated confirmed symptomatic COVID-19 cases accrued up to a data cut-off date of October 8, 2021.

Table 27 presents the specific demographic characteristics in participants who did not have evidence of prior infection with SARS-CoV-2 through 7 days after the second dose.

**Table 27: Demographics Characteristics – Participants Without Evidence of Infection Prior to 7 Days After Dose 2 – Phase 2/3 – 5 Years Through <12 Years of Age – Evaluable Efficacy Population (Data Accrued Through October 8, 2021)**

	<b>COMIRNATY<sup>†</sup> 10 mcg/dose (N<sup>a</sup>=1,305) n<sup>b</sup> (%)</b>	<b>Placebo (N<sup>a</sup>=663) n<sup>b</sup> (%)</b>
<b>Sex</b>		
Male	679 (52.0)	343 (51.7)
Female	626 (48.0)	320 (48.3)
<b>Age at Vaccination</b>		
Mean (SD)	8.2 (1.93)	8.1 (1.98)
Median	8.0	8.0
Min, max	(5, 11)	(5, 11)
<b>Race</b>		
White	1,018 (78.0)	514 (77.5)
Black or African American	76 (5.8)	48 (7.2)
American Indian or Alaska Native	<1.0%	<1.0%
Asian	86 (6.6)	46 (6.9)
Native Hawaiian or other Pacific Islander	<1.0%	<1.0%
Other <sup>c</sup>	110 (8.4)	52 (7.8)
<b>Ethnicity</b>		
Hispanic or Latino	243 (18.6)	130 (19.6)
Not Hispanic or Latino	1059 (81.1)	533 (80.4)
Not reported	<1.0%	<1.0%
<b>Comorbidities<sup>d</sup></b>		
Yes	262 (20.1)	133 (20.1)
No	1043 (79.9)	530 (79.9)

<sup>†</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = number of participants in the specified group from the evaluable efficacy population with no evidence of SARS CoV-2 infection prior to 7 days after Dose 2. This value is the denominator for the percentage calculations. Evaluable efficacy population included all eligible randomized participants who received all vaccination(s) as randomized within the predefined window, had no other important protocol deviations as determined by the clinician.

b. n = Number of participants with the specified characteristic.

c. Includes multiracial and not reported.

d. Number of participants who have 1 or more comorbidities that increase the risk of severe COVID-19 disease: defined as participants who had at least 1 of the prespecified comorbidities based on MMWR 69(32);1081-1088 and/or obesity (BMI ≥95<sup>th</sup> percentile).

#### 14.1.5 COMIRNATY (Original: 3 mcg)

**Participants 2 Through <5 Years of Age:** The evaluable immunogenicity population without prior evidence of SARS-CoV-2 infection up to 1 month after Dose 3 of COMIRNATY was comprised of 143 participants 2 through <5 years of age. Most participants in this analysis population were White (69.2%), with 5.6% Black or African American participants, 11.2% Asian participants, and 11.9% multiracial participants. There were 11.2% Hispanic/Latino participants. The median age was 3.0 years and 44.1% of participants were male. There were 6.3% of participants reported as obese. In the evaluable immunogenicity population (regardless of evidence of prior infection), 11/204 participants (5.4%) were baseline positive for prior SARS-CoV-2 infection.

**Participants 6 Months Through <2 Years of Age:** The evaluable immunogenicity population without prior evidence of SARS-CoV-2 infection up to 1 month after Dose 3 of COMIRNATY was comprised of 82 participants 6 months through <2 years of age. Most participants in this analysis population were White (72.0%), with 1.2% Black or African American participants, 13.4% Asian participants, and 12.2% multiracial participants. There were 15.9% Hispanic/Latino participants. The median age was 16.0 months and 62.2% of participants were male. In the evaluable immunogenicity population (regardless of evidence of prior infection), 6/132 participants (4.5%) were baseline positive for prior SARS-CoV-2 infection.

### 14.2 Study Results

#### 14.2.1 COMIRNATY Original & Omicron BA.4/BA.5 (15/15mcg)

##### 14.2.1.1 Immunogenicity in Participants 12 Years of Age and Older – After Second Booster Dose (Fourth Dose)

In an analysis of a subset from Study 5, 105 participants 12 to 17 years of age, 297 participants 18 to 55 years of age, and 286 participants 56 years of age and older who had previously received a 2-dose primary series and 1 booster dose with COMIRNATY (original vaccine) received a second booster (fourth) dose of COMIRNATY Original & Omicron BA.4/BA.5 (15/15 mcg, bivalent vaccine). In participants 12 to 17 years of age, 18 to 55 years of age, and 56 years of age and older, 75.2%, 71.7% and 61.5% were positive for SARS-CoV-2 at baseline, respectively.

Analyses of 50% neutralizing antibody titers (NT50) against Omicron BA.4/BA.5 and against reference strain among participants 56 years of age and older who received a second booster dose of COMIRNATY Original & Omicron BA.4/5 in Study 5 compared to a subset of participants from Study 4 who received a second booster dose of COMIRNATY demonstrated superiority of COMIRNATY Original & Omicron BA.4/BA.5 to COMIRNATY based on geometric mean ratio (GMR) and noninferiority based on difference in seroresponse rates with respect to anti-Omicron BA.4/BA.5 response, and noninferiority of anti-reference strain immune response based on GMR (Table 28 and Table 29).

Analyses of NT50 against Omicron BA.4/BA.5 among participants 18 through 55 years of age compared to participants 56 years of age and older who received a second booster dose of COMIRNATY Original & Omicron BA.4/BA.5 in Study 5 demonstrated noninferiority of anti-Omicron BA.4/BA.5 response among participants 18 through 55 years of age compared to participants 56 years of age and older for both GMR and difference in seroresponse rates (Table 28 and Table 29).

The study also assessed the level of NT50 of the anti-Omicron BA.4/BA.5 SARS-CoV-2 strains pre-vaccination and 1 month after vaccination in participants who received a second booster dose (Table 30).

**Table 28: Geometric Mean Ratios – Study 5 – Participants With or Without Evidence of Infection – Evaluable Immunogenicity Population**

SARS-CoV-2 Neutralization Assay	Sampling Time Point <sup>a</sup>	COMIRNATY Original & Omicron BA.4/BA.5 Study 5				COMIRNATY <sup>†</sup> Subset of Study 4		Age Group Comparison	Vaccine Group Comparison
		18 Through 55 Years of Age		56 Years of Age and Older		56 Years of Age and Older		COMIRNATY Original & Omicron BA.4/BA.5 18 Through 55 Years of Age/≥ 56 Years of Age	≥ 56 Years of age COMIRNATY Original & Omicron BA.4/BA.5 /COMIRNATY
		n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	GMR <sup>d</sup> (95% CI <sup>d</sup> )	GMR <sup>d</sup> (95% CI <sup>d</sup> )
Omicron BA.4/BA.5 – NT50 (titer) <sup>e</sup>	1 month	297	4455.9 (3851.7, 5154.8)	284	4158.1 (3554.8, 4863.8)	282	938.9 (802.3, 1098.8)	0.98 (0.83, 1.16) <sup>f</sup>	2.91 (2.45, 3.44) <sup>g</sup>
Reference Strain – NT50 (titer) <sup>e</sup>	1 month	-	-	286	16250.1 (14499.2, 18212.4)	289	10415.5 (9366.7, 11581.8)	-	1.38 (1.22, 1.56) <sup>h</sup>

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

<sup>†</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- Protocol-specified timing for blood sample collection.
- n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.
- GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
- GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of LS means and corresponding CIs based on analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of baseline neutralizing titer (log scale) and vaccine group or age group.
- SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (original strain [USA-WA1/2020, isolated in January 2020] and Omicron B.1.1.529 subvariant BA.4/BA.5).
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67.
- Superiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 1.
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67 and the point estimate of the GMR is ≥ 0.8.



**Table 29: Difference in Percentages of Participants with Seroresponse – COMIRNATY Original & Omicron BA.4/BA.5 from Study 5 and COMIRNATY from Subset of Study 4 – Participants With or Without Evidence of Infection – Evaluable Immunogenicity Population**

SARS-CoV-2 Neutralization Assay	Sampling Time Point <sup>a</sup>	COMIRNATY Original & Omicron BA.4/BA.5 Study 5				COMIRNATY <sup>‡</sup> Subset of Study 4		Age Group Comparison	Vaccine Group Comparison
		18 Through 55 Years of Age		56 Years of Age and Older		56 Years of Age and Older		COMIRNATY Original & Omicron BA.4/BA.5 18 Through 55 Years of Age/ ≥ 56 Years of Age	COMIRNATY Original & Omicron BA.4/BA.5 /COMIRNATY ≥ 56 Years of Age
		n <sup>b</sup>	N <sup>c</sup> (%) (95% CI <sup>d</sup> )	n <sup>b</sup>	N <sup>c</sup> (%) (95% CI <sup>d</sup> )	n <sup>b</sup>	N <sup>c</sup> (%) (95% CI <sup>d</sup> )	Difference <sup>e</sup> (95% CI <sup>f</sup> )	Difference <sup>e</sup> (95% CI <sup>f</sup> )
Omicron BA.4/BA.5 – NT50 (titer) <sup>g</sup>	1 month	294	180 (61.2) (55.4, 66.8)	282	188 (66.7) (60.8, 72.1)	273	127 (46.5) (40.5, 52.6)	-3.03 (-9.68, 3.63) <sup>h</sup>	26.77 (19.59, 33.95) <sup>i</sup>

Abbreviations: CI = confidence interval; LLOQ = lower limit of quantitation; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

Note: Seroresponse is defined as achieving a ≥ 4-fold rise from baseline. If the baseline measurement is below the LLOQ, a postvaccination assay result ≥ 4 × LLOQ is considered a seroresponse.

- Protocol-specified timing for blood sample collection.
- N = Number of participants with valid and determinate assay results for the specified assay at both the prevaccination time point and the given sampling time point. This value is the denominator for the percentage calculation.
- n = Number of participants with seroresponse for the given assay at the given sampling time point.
- Exact 2-sided CI, based on the Clopper and Pearson method.
- Difference in proportions, expressed as a percentage.
- 2-sided CI based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category (< median, ≥ median) for the difference in proportions. The median of baseline neutralizing titers was calculated based on the pooled data in 2 comparator groups.
- SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (Omicron B.1.1.529 subvariant BA.4/BA.5).
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the difference in percentages of participants with seroresponse is > -10%.
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the difference in percentages of participants with seroresponse is > -5%.

**Table 30: Geometric Mean Titers by Baseline SARS-CoV-2 Status – COMIRNATY Original & Omicron BA.4/BA.5) Groups Subset of Study 5 – Prior to and 1 Month After Second Booster – Participants 12 Years of Age and Older – Evaluable Immunogenicity Population**

SARS-CoV-2 Neutralization Assay	Baseline SARS-CoV-2 Status	Sampling Time Point <sup>a</sup>	COMIRNATY Original & Omicron BA.4/BA.5					
			12 Through 17 Years of Age		18 Through 55 Years of Age		56 Years of Age and Older	
			n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )
Omicron BA.4/BA.5 – NT50 (titer) <sup>f</sup>	All	Pre-vaccination	104	1105.8 (835.1, 1464.3)	294	569.6 (471.4, 688.2)	284	458.2 (365.2, 574.8)
		1 Month	105	8212.8 (6807.3, 9908.7)	297	4455.9 (3851.7, 5154.8)	284	4158.1 (3554.8, 4863.8)
	Positive <sup>d</sup>	Pre-vaccination	78	1791.1 (1379.6, 2325.3)	210	1181.4 (1005.3, 1388.3)	174	1291.7 (1027.5, 1623.8)
		1 Month	79	9892.5 (8114.6, 12059.8)	213	6031.6 (5203.9, 6991.0)	176	6688.9 (5664.4, 7898.8)
	Negative <sup>e</sup>	Pre-vaccination	26	260.2 (157.1, 430.9)	84	91.9 (71.5, 118.1)	110	88.9 (69.8, 113.4)
		1 Month	26	4666.1 (3096.1, 7032.2)	84	2067.7 (1530.2, 2793.9)	108	1916.2 (1489.5, 2465.1)
Reference Strain – NT50 (titer) <sup>f</sup>	All	Pre-vaccination	105	6863.3 (5587.8, 8430.1)	296	4017.3 (3430.7, 4704.1)	284	3690.6 (3082.2, 4419.0)
		1 Month	105	23641.3 (20473.1, 27299.8)	296	16323.3 (14686.5, 18142.6)	286	16250.1 (14499.2, 18212.4)
	Positive <sup>d</sup>	Pre-vaccination	79	8685.4 (7062.7, 10680.9)	213	7068.6 (6251.9, 7992.0)	174	8082.1 (6843.6, 9544.8)
		1 Month	79	25991.8 (22377.5, 30189.8)	212	19076.6 (17056.5, 21336.0)	176	21273.3 (18604.2, 24325.3)
	Negative <sup>e</sup>	Pre-vaccination	26	3356.2 (2106.9, 5346.2)	83	942.3 (705.6, 1258.3)	110	1068.0 (835.9, 1364.6)
		1 Month	26	17725.2 (12376.4, 25385.7)	84	11014.6 (8793.9, 13796.0)	110	10560.6 (8827.1, 12634.5)

Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

- Protocol-specified timing for blood sample collection.
- n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.
- GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
- Positive N-binding antibody result at baseline, positive NAAT result at baseline, or medical history of COVID-19.
- Negative N-binding antibody result at baseline, negative NAAT result at baseline, and no medical history of COVID-19.
- SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (original strain [USA-WA1/2020, isolated in January 2020] and Omicron B.1.1.529 subvariant BA.4/BA.5).

## 14.2.2 COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg)

### 14.2.2.1 Immunogenicity in Participants 6 Months Through <5 Years of Age – After Booster (Fourth Dose)

In Study 6, a subset of 60 participants 6 months through <5 years of age received a booster (fourth dose) of COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg) after receiving 3 prior doses of COMIRNATY 3 mcg. Neutralizing antibody levels following the fourth dose are presented in Table 31. Data from a subset of participants 6 months through <5 years of age in Study 3 who received 3 doses of COMIRNATY 3 mcg are included as a reference.

At 1 month after a booster dose (fourth dose), COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg) elicited higher Omicron BA.4/BA.5 specific neutralizing titers (regardless of baseline SARS-CoV-2 status) compared with the titers in the comparator group who received 3 doses of COMIRNATY 3 mcg. COMIRNATY Original & Omicron BA.4/BA.5 (1.5/1.5 mcg) also elicited similar reference strain-specific titers compared with the titers in the comparator group.

**Table 31: Geometric Mean Titers – Study 6 Subset – Participants With or Without Evidence of Infection – 6 Months Through < 5 Years of Age – Evaluable Immunogenicity Population**

SARS-CoV-2 Neutralization Assay	Age Group	Baseline (Dose 4 Study 6/ Dose 3 Study 3) SARS-CoV-2 Status	Sampling Time Point <sup>a</sup>	Vaccine Group (as Assigned/Randomized)			
				Study 6 COMIRNATY Original & Omicron BA.4/BA.5 1.5/1.5 mcg Dose 4 and 1 Month After Dose 4		Study 3 COMIRNATY <sup>‡</sup> 3 mcg Dose 3 and 1 Month After Dose 3	
				n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )
Omicron BA.4/BA.5 - NT50 (titer) <sup>d</sup>	6 months through <5 years	Overall	Pre-vaccination	54	192.5 (120.4, 307.8)	54	70.5 (51.1, 97.2)
			1 month	58	1695.2 (1151.8, 2494.9)	54	607.9 (431.1, 857.2)
		Positive <sup>e</sup>	Pre-vaccination	16	1315.4 (789.1, 2192.8)	15	351.7 (195.2, 633.8)
			1 month	16	4897.7 (3085.5, 7774.1)	15	1785.9 (1009.4, 3159.9)
		Negative <sup>f</sup>	Pre-vaccination	38	85.7 (56.6, 129.8)	36	38.2 (34.2, 42.8)
			1 month	41	1116.0 (701.3, 1776.1)	36	416.2 (287.8, 602.0)

---

Abbreviations: CI = confidence interval; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- a. Protocol-specified timing for blood sample collection.
- b. n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.
- c. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times$  LLOQ.
- d. SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (Omicron B.1.1.529 subvariant BA.4/BA.5).
- e. For Study 6: positive N-binding antibody result at Dose 4 visit, positive NAAT result at Dose 4 visit, or medical history of COVID-19. For Study 3: positive N-binding antibody result at Dose 1, 1-month post-Dose 2 (if available), or Dose 3 visits, positive NAAT result at Dose 1, Dose 2, Dose 3, or any unscheduled illness visit up to Dose 3 visit, or medical history of COVID-19.
- f. For Study 6: negative N-binding antibody result at Dose 4 visit, negative NAAT result at Dose 4 visit, and no medical history of COVID-19. For Study 3: negative N-binding antibody result at Dose 1, 1-month post-Dose 2 (if available), and Dose 3 visits, negative NAAT result at Dose 1, Dose 2, Dose 3, and any unscheduled illness visits up to Dose 3 visit, and no medical history of COVID-19.

### **14.2.3 COMIRNATY (Original: 30 mcg)**

#### **14.2.3.1 Efficacy and Immunogenicity in Participants 16 Years of Age and Older**

##### **14.2.3.1.1 Efficacy in Participants 16 Years of Age and Older – After Two Doses**

##### Primary Vaccine Efficacy Analysis (Based on Cut-off Date of November 14, 2020)

At the time of the primary efficacy analysis, participants had been followed for symptomatic COVID19 for at least 2,214 personyears in the COMIRNATY group and at least 2,222 personyears in the placebo group.

There were no meaningful clinical differences in overall vaccine efficacy in participants who were at risk of severe COVID-19 including those with 1 or more comorbidities that increase the risk of severe COVID-19 [e.g., asthma, body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup>, chronic pulmonary disease, diabetes mellitus, hypertension]. The primary endpoint was defined as any symptomatic COVID-19 case<sup>1</sup> confirmed by Reverse Transcription-Polymerase Chain Reaction (RT-PCR). The population for the analysis of the primary efficacy endpoint included participants who did not have evidence of prior infection with SARS-CoV-2 through 7 days after the second dose (first primary efficacy endpoint), as well as participants with and without evidence of prior infections with SARS-CoV-2 through 7 days after the second dose (second primary efficacy endpoint). The pre-specified success criterion for vaccine efficacy was met. The vaccine efficacy information is presented in Table 32.

---

<sup>1</sup> Case definition defined by Study 2 protocol: (at least 1 of) fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea or vomiting.

**Table 32: Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Age Subgroup – Participants Without Evidence of Infection and Participants With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population (Data Accrued Through November 14, 2020)**

<b>First COVID-19 occurrence from 7 days after Dose 2 in participants without evidence of prior SARS-CoV-2 infection*</b>			
<b>Subgroup</b>	<b>COMIRNATY<sup>‡</sup> N<sup>a</sup>=18,198 Cases (n<sup>1b</sup>) Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Placebo N<sup>a</sup>=18,325 Cases (n<sup>1b</sup>) Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Vaccine Efficacy % (95% CI)</b>
All participants <sup>e</sup>	8 2.214 (17,411)	162 2.222 (17,511)	95.0 (90.3, 97.6) <sup>f</sup>
16 through 64 years	7 1.706 (13,549)	143 1.710 (13,618)	95.1 (89.6, 98.1) <sup>g</sup>
65 years and older	1 0.508 (3,848)	19 0.511 (3,880)	94.7 (66.7, 99.9) <sup>g</sup>
<b>First COVID-19 occurrence from 7 days after Dose 2 in participants with or without* evidence of prior SARS-CoV-2 infection</b>			
<b>Subgroup</b>	<b>COMIRNATY<sup>‡</sup> N<sup>a</sup>=19,965 Cases (n<sup>1b</sup>) Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Placebo N<sup>a</sup>=20,172 Cases (n<sup>1b</sup>) Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Vaccine Efficacy % (95% CI)</b>
All participants <sup>e</sup>	9 2.332 (18,559)	169 2.345 (18,708)	94.6 (89.9, 97.3) <sup>f</sup>
16 through 64 years	8 1.802 (14,501)	150 1.814 (14,627)	94.6 (89.1, 97.7) <sup>g</sup>
65 years and older	1 0.530 (4,044)	19 0.532 (4,067)	94.7 (66.8, 99.9) <sup>g</sup>

Note: Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 (symptoms included: fever; new or increased cough; new or increased shortness of breath; chills; new or increased muscle pain; new loss of taste or smell; sore throat; diarrhea; vomiting).

Abbreviations: NAAT = nucleic acid amplification test; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; VE = vaccine efficacy.

\* Participants who had no evidence of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose 2 were included in the analysis.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = number of participants in the specified group.

b. n1 = Number of participants meeting the endpoint definition.

c. Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.

d. n2 = Number of participants at risk for the endpoint.

e. No confirmed cases were identified in adolescents 12 to 15 years of age.

f. Two-sided credible interval for vaccine efficacy (VE) was calculated using a beta-binomial model with a beta (0.700102, 1) prior for  $\theta = r(1-VE)/(1+r(1-VE))$ , where r is the ratio of surveillance time in the active vaccine group over that in the placebo group.

g. Two-sided confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted to the surveillance time.

Updated Vaccine Efficacy (Based on Cut-off Date of March 13, 2021)

Updated efficacy analyses were performed with additional confirmed COVID-19 cases accrued during blinded placebo-controlled follow-up through March 13, 2021, representing up to 6 months of follow-up after Dose 2 for participants in the efficacy population. There were 77 confirmed COVID-19 cases identified in the COMIRNATY and 850 in the placebo groups, respectively. In this analysis, compared to placebo, the vaccine efficacy of COMIRNATY in participants without evidence of SARS-CoV-2 infection prior to 7 days after Dose 2 was 91.3% (95% confidence interval of 89.0% to 93.2%); in participants 65 years of age and older without evidence of prior infection vaccine efficacy was 94.5% (two-sided 95% confidence interval 88.3% to 97.8%). The vaccine efficacy of COMIRNATY in participants with or without evidence of prior infection was 91.1% (95% confidence interval: 88.8% to 93.0%) with 81 COVID-19 cases in the COMIRNATY group compared to 873 cases in the placebo group.

Efficacy Against Severe COVID-19 (Based on Cut-off Date of March 13, 2021)

Secondary efficacy analyses in Study 2 supported benefit of COMIRNATY in preventing severe COVID-19. During blinded placebo-controlled follow-up through March 13, 2021, the vaccine efficacy against severe COVID 19 (as defined by the study protocol) in participants **with or without evidence** of SARS-CoV-2 infection prior to 7 days after Dose 2 was 95.3% (95% CI: 70.9%, 99.9%) with 1 and 21 cases in the vaccine and placebo groups, respectively. The COVID-19 case counts in participants without prior SARS-CoV-2 infection were the same as those in participants with or without prior SARS-CoV-2 infection in both the COMIRNATY and placebo groups.

**14.2.3.1.2 Efficacy and Immunogenicity in Participants 16 Years of Age and Older – After Booster Dose**Immunogenicity in Participants 18 to 55 Years of Age – After Booster Dose

Noninferiority of immune responses 1 month after a COMIRNATY booster dose compared to 1 month after completion of the primary 2-dose series was assessed, in a subset of participants enrolled at selected sites in the US, by evaluating SARS-CoV-2 50% neutralizing titers (NT50) against the reference strain. Immunogenicity was evaluated in subjects who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after the booster vaccination. The analysis demonstrated noninferior immune responses 1 month after a booster dose compared to 1 month after Dose 2 in individuals 18 through 55 years of age (Table 33).

**Table 33: SARS-CoV-2 Neutralization Assay – NT50 (titer)<sup>†</sup> – GMT and Seroresponse Rate Comparison of 1 Month After Booster Dose to 1 Month After Primary Series – Participants Without Evidence of Infection up to 1 Month After Booster Dose\* – Booster Dose Evaluable Immunogenicity Population**

Assay	n	COMIRNATY <sup>‡</sup> Sampling Time Point		1 month after booster dose/ - 1 month after primary series (97.5% CI)	Met noninferiority objective (Y/N)
		1 month after booster dose (95% CI)	1 month after Dose 2 (95% CI)		
Geometric mean 50% neutralizing titer (GMT <sup>b</sup> )	210 <sup>a</sup>	2,476.4 <sup>b</sup> (2,210.1, 2774.9)	753.7 <sup>b</sup> (658.2, 863.1)	3.29 <sup>c</sup> (2.76, 3.91)	Y <sup>d</sup>
Seroresponse rate (%) for 50% neutralizing titer	198 <sup>e</sup>	197 <sup>f</sup> 99.5% (97.2%, 100.0%)	194 <sup>f</sup> 98.0% (94.4%, 99.4%)	1.5% <sup>g</sup> (-0.7%, 3.7% <sup>h</sup> )	Y <sup>i</sup>

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Y/N = yes/no.

<sup>†</sup> SARS-CoV-2 NT50 were determined using the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay. The assay uses a fluorescent reporter virus derived from the USA\_WA1/2020 strain and virus neutralization is read on Vero cell monolayers. The sample NT50 is defined as the reciprocal serum dilution at which 50% of the virus is neutralized.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

\* Participants who had no serological or virological evidence (up to 1 month after receipt of a booster dose of COMIRNATY) of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative and SARS-CoV-2 not detected by NAAT [nasal swab]) and had a negative NAAT (nasal swab) at any unscheduled visit up to 1 month after the booster dose were included in the analysis.

a. n = Number of participants with valid and determinate assay results at both sampling time points within specified window.

b. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

c. GMRs and 2-sided 97.5% CIs were calculated by exponentiating the mean differences in the logarithms of the assay and the corresponding CIs (based on the Student t distribution).

d. Noninferiority is declared if the lower bound of the 2-sided 97.5% CI for the GMR is >0.67 and the point estimate of the GMR is ≥0.80.

e. n = Number of participants with valid and determinate assay results for the specified assay at baseline, 1 month after Dose 2 and 1 month after the booster dose within specified window. These values are the denominators for the percentage calculations.

f. Number of participants with seroresponse for the given assay at the given dose/sampling time point. Exact 2-sided CI based on the Clopper and Pearson method. Note: Seroresponse is defined as achieving a ≥4-fold rise from baseline (before Dose 1). If the baseline measurement is below the LLOQ, a postvaccination assay result ≥4 × LLOQ is considered a seroresponse.

g. Difference in proportions, expressed as a percentage (1 month after booster dose – 1 month after Dose 2).

h. Adjusted Wald 2-sided CI for the difference in proportions, expressed as a percentage.

i. Noninferiority is declared if the lower bound of the 2-sided 97.5% CI for the percentage difference is >-10%.

### Relative Vaccine Efficacy in Participants 16 Years of Age and Older – After Booster Dose

An interim efficacy analysis of Study 4, a placebo-controlled booster study was performed in approximately 10,000 participants 16 years of age and older who were recruited from Study 2 and evaluated confirmed COVID-19 cases accrued from at least 7 days after booster vaccination up to a data cut-off date of 5 October 2021, which represents a median of 2.5 months post-booster follow-up. Vaccine efficacy of the COMIRNATY booster dose after the primary series relative to the placebo booster group who only received the primary series dose was assessed. The relative vaccine efficacy information for participants 16 years of age and older is presented in Table 34.

**Table 34: Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Booster Vaccination – Participants 16 Years of Age and Older Without Evidence of Infection and Participants With or Without Evidence of Infection Prior to 7 Days After Booster Vaccination – Evaluable Efficacy Population**

<b>First COVID-19 occurrence from 7 days after booster dose in participants without evidence of prior SARS-CoV-2 infection*</b>			
	<b>COMIRNATY<sup>‡</sup> N<sup>a</sup>=4,695 Cases (n1<sup>b</sup>) Surveillance Time<sup>c</sup> (n2<sup>d</sup>)</b>	<b>Placebo N<sup>a</sup>=4,671 Cases (n1<sup>b</sup>) Surveillance Time<sup>c</sup> (n2<sup>d</sup>)</b>	<b>Relative Vaccine Efficacy<sup>e</sup> % (95% CI<sup>f</sup>)</b>
First COVID-19 occurrence from 7 days after booster vaccination	6 0.823 (4,659)	123 0.792 (4,614)	95.3 (89.5, 98.3)
<b>First COVID-19 occurrence from 7 days after booster dose in participants with or without evidence of prior SARS-CoV-2 infection</b>			
	<b>COMIRNATY<sup>‡</sup> N<sup>a</sup>=4,993 Cases (n1<sup>b</sup>) Surveillance Time<sup>c</sup> (n2<sup>d</sup>)</b>	<b>Placebo N<sup>a</sup>=4,952 Cases (n1<sup>b</sup>) Surveillance Time<sup>c</sup> (n2<sup>d</sup>)</b>	<b>Relative Vaccine Efficacy<sup>e</sup> % (95% CI<sup>f</sup>)</b>
First COVID-19 occurrence from 7 days after booster vaccination	7 0.871 (4,934)	124 0.835 (4,863)	94.6 (88.5, 97.9)

Note: Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 (symptoms included: fever; new or increased cough; new or increased shortness of breath; chills; new or increased muscle pain; new loss of taste or smell; sore throat; diarrhea; vomiting).

\* Participants who had no serological or virological evidence (prior to 7 days after receipt of the booster vaccination) of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visit 1, and had a negative NAAT [nasal swab] at any unscheduled visit prior to 7 days after booster vaccination) were included in the analysis.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants in the specified group.

b. n1 = Number of participants meeting the endpoint definition.

c. Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after the booster vaccination to the end of the surveillance period.

d. n2 = Number of participants at risk for the endpoint.

e. Relative vaccine efficacy of the COMIRNATY booster group relative to the placebo group (non-booster).

f. Two-sided confidence interval (CI) for relative vaccine efficacy is derived based on the Clopper and Pearson method adjusted for surveillance time.



### 14.2.3.2 Efficacy and Immunogenicity in Adolescents 12 to 15 Years of Age

#### 14.2.3.2.1 Efficacy and Immunogenicity in Adolescents 12 to 15 Years of Age – After Two Doses

##### Efficacy

The vaccine efficacy in participants 12 to 15 years of age was evaluated on a subgroup analysis of Study 2 based on a cut-off date of March 13, 2021 (Table 35).

**Table 35: Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, Without Evidence of Infection and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period (Data Accrued Through March 13, 2021), Adolescents 12 to 15 Years of Age Evaluable Efficacy (7 Days) Population**

<b>First COVID-19 occurrence from 7 days after Dose 2 in adolescents 12 to 15 years of age without evidence of prior SARS-CoV-2 infection*</b>			
	<b>COMIRNATY<sup>‡</sup> N<sup>a</sup>=1,005 Cases (n<sup>1b</sup>) Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Placebo N<sup>a</sup>=978 Cases (n<sup>1b</sup>) Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Vaccine Efficacy % (95% CI<sup>e</sup>)</b>
Adolescents 12 to 15 Years of Age	0 0.154 (1,001)	16 0.147 (972)	100.0 (75.3, 100.0)
<b>First COVID-19 occurrence from 7 days after Dose 2 in adolescents 12 to 15 years of age with or without* evidence of prior SARS-CoV-2 infection</b>			
	<b>COMIRNATY<sup>‡</sup> N<sup>a</sup>=1,119 Cases (n<sup>1b</sup>) Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Placebo N<sup>a</sup>=1,110 Cases (n<sup>1b</sup>) Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Vaccine Efficacy % (95% CI<sup>e</sup>)</b>
Adolescents 12 to 15 Years of Age	0 0.170 (1,109)	18 0.163 (1094)	100.0 (78.1, 100.0)

Note: Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 (symptoms included: fever; new or increased cough; new or increased shortness of breath; chills; new or increased muscle pain; new loss of taste or smell; sore throat; diarrhea; vomiting).

\* Participants who had no evidence of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose 2 were included in the analysis.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants in the specified group.

b. n1 = Number of participants meeting the endpoint definition.

c. Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.

d. n2 = Number of participants at risk for the endpoint.

e. Confidence interval (CI) for vaccine efficacy is derived based on the Clopper and Pearson method adjusted for surveillance time.

An updated efficacy analysis of Study 2 has been performed in approximately 2,260 adolescents 12 through 15 years of age evaluating confirmed COVID-19 cases accrued up to a data cut-off date of September 2, 2021, representing up to 6 months of follow-up after Dose 2 for participants in the efficacy population.

In the adolescent group, in efficacy analyses in the evaluable efficacy population based on cases reported from at least 7 days after Dose 2 through the data cut-off date (02 September 2021), representing a median of 4.4 (range 0-10.8) months of follow-up after Dose 2, there were 0 confirmed COVID-19 cases identified in the COMIRNATY and 28 in the placebo groups, respectively. In this analysis, compared to placebo, the estimated VE against confirmed COVID-19 was 100% (95% CI: 86.8%, 100%) for individuals without evidence of prior SARS-CoV-2 infection before and during vaccination regimen. The estimated VE against confirmed COVID-19 was 100% (2-sided 95% CI: 87.5%, 100%) for those with or without evidence of prior SARS-CoV-2 infection before and during vaccination regimen, with 0 COVID-19 cases in the COMIRNATY group compared to 30 cases in the placebo group.

Among participants without and with or without evidence of SARS-CoV-2 infection before and during the vaccination regimen (evaluable efficacy population), VE against COVID-19 occurring at least 7 days after Dose 2 was evaluated for demographic and risk subgroups, and the estimated VE was 100.0% for all subgroups.

#### Immunogenicity – After Two Doses

In Study 2, an analysis of SARS-CoV-2 50% neutralizing titers (NT50) 1 month after Dose 2 in a randomly selected subset of participants demonstrated non-inferior immune responses (within 1.5-fold) comparing adolescents 12 through 15 years of age to participants 16 through 25 years of age who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after Dose 2 (Table 36).

**Table 36: Summary of Geometric Mean Ratio for 50% Neutralizing Titer – Comparison of Adolescents 12 Through 15 Years of Age to Participants 16 Through 25 Years of Age (Immunogenicity Subset) – Participants Without Evidence of Infection up to 1 Month After Dose 2 – Dose 2 Evaluable Immunogenicity Population**

		COMIRNATY <sup>‡</sup>		12 Through 15 Years/ 16 Through 25 Years	
		12 Through 15 Years n <sup>a</sup> =190	16 Through 25 Years n <sup>a</sup> =170		
Assay	Time Point <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	GMT <sup>c</sup> (95% CI <sup>c</sup> )	GMR <sup>d</sup> (95% CI <sup>d</sup> )	Met Noninferiority Objective <sup>e</sup> (Y/N)
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>f</sup>	1 month after Dose 2	1,239.5 (1,095.5, 1,402.5)	705.1 (621.4, 800.2)	1.76 (1.47, 2.10)	Y

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic-acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Participants who had no serological or virological evidence (up to 1 month after receipt of the last dose) of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 were included in the analysis.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. n = Number of participants with valid and determinate assay results for the specified assay at the given dose/sampling time point.

b. Protocol-specified timing for blood sample collection.

- 
- c. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times \text{LLOQ}$ .
  - d. GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (Group 1 [12 through 15 years of age] – Group 2 [16 through 25 years of age]) and the corresponding CI (based on the Student t distribution).
  - e. Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67.
  - f. SARS-CoV-2 NT50 were determined using the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay. The assay uses a fluorescent reporter virus derived from the USA\_WA1/2020 strain and virus neutralization is read on Vero cell monolayers. The sample NT50 is defined as the reciprocal serum dilution at which 50% of the virus is neutralized.

### **14.2.3.3 Coadministration of COMIRNATY with Influenza Vaccine**

In Study 8 (C4591030), a Phase 3, multicenter, randomized, observer-blind study, 1,134 participants 18 through 64 years of age who had received 3 doses of COMIRNATY at least 3 months prior were randomized in a 1:1 ratio to receive either COMIRNATY coadministered with a standard dose unadjuvanted seasonal inactivated influenza vaccine (SIIV), quadrivalent followed 1 month later by placebo (Group 1, n=568) or SIIV quadrivalent with placebo followed 1 month later with COMIRNATY (Group 2, n=566).

Following administration of COMIRNATY concomitantly with SIIV, the criteria for non-inferiority of the immune responses were met as lower limits of 2-sided 95% confidence interval on the group geometric mean titer ratios were above the predefined noninferiority criterion of 0.67 for both full-length S-binding immunoglobulin G (IgG) and all 4 influenza strain-specific haemagglutinin inhibition antibodies.

### **14.2.4 COMIRNATY (Original: 10 mcg)**

#### **14.2.4.1 Efficacy and Immunogenicity in Children 5 Years Through <12 Years of Age**

##### **14.2.4.1.1 Efficacy and Immunogenicity in Children 5 Years Through <12 Years of Age – After Two Doses**

##### Immunogenicity

In Study 3, an analysis of SARS-CoV-2 50% neutralizing titers (NT50) 1 month after Dose 2 in a randomly selected subset of participants demonstrated effectiveness by immunobridging of immune responses. Children 5 years through <12 years of age in the Phase 2/3 part of Study 3 were compared to participants 16 through 25 years of age in the Phase 2/3 part of Study 2 who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after Dose 2. The study met the prespecified immunobridging criteria for both the geometric mean ratio (GMR) and the seroresponse difference with seroresponse defined as achieving at least 4-fold rise in SARS-CoV-2 NT50 from baseline (before Dose 1). The ratio of the SARS-CoV-2 NT50 in children 5 years through <12 years of age to that of young adults 16 to 25 years of age was 1.04 (2-sided 95% CI: 0.93, 1.18), meeting the 1.5-fold noninferiority criterion (the lower bound of the 2-sided 95% CI for the geometric mean ratio [GMR] >0.67). Results are presented in Table 37.

**Table 37: Summary of Geometric Mean Ratio for 50% Neutralizing Titer And Difference in Percentages of Participants with Seroreponse – Comparison of Children 5 Years Through < 12 Years of Age (Study 3) to Participants 16 Through 25 Years of Age (Study 2) – Participants Without Evidence of Infection up to 1 Month After Dose 2 – Immunobridging Subset – Dose 2 Evaluable Immunogenicity Population**

Geometric Mean Titers (NT50)					
		COMIRNATY <sup>‡</sup>		5 Years Through <12 Years/ 16 Through 25 Years	
		10 mcg/Dose 5 Years Through <12 Years N <sup>a</sup> =264	30 mcg/Dose 16 Through 25 Years N <sup>a</sup> =253		
Assay	Time Point <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	GMT <sup>c</sup> (95% CI <sup>c</sup> )	GMR <sup>d</sup> (95% CI <sup>d</sup> )	Met Immunobridging Objective <sup>e</sup> (Y/N)
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>f</sup>	1 month after Dose 2	1,197.6 (1,106.1, 1,296.6)	1,146.5 (1,045.5, 1,257.2)	1.04 (0.93, 1.18)	Y
Seroreponse Rate					
		COMIRNATY		5 Years Through <12 Years/ 16 Through 25 Years	
		10 mcg/Dose 5 Years Through <12 Years N <sup>e</sup> =264	30 mcg/Dose 16 Through 25 Years N <sup>e</sup> =253		
Assay	Time Point <sup>b</sup>	n <sup>h</sup> (%) (95% CI <sup>i</sup> )	n <sup>h</sup> (%) (95% CI <sup>i</sup> )	Difference % <sup>j</sup> (95% CI <sup>k</sup> )	Met Immunobridging Objective <sup>l</sup> (Y/N)
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>f</sup>	1 month after Dose 2	262 (99.2) (97.3, 99.9)	251 (99.2) (97.2, 99.9)	0.0 (-2.0, 2.2)	Y

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic-acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Participants who had no serological or virological evidence (up to 1 month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and 1 month after Dose 2, SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2, and negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 blood collection) and had no medical history of COVID-19 were included in the analysis.

Note: Seroreponse is defined as achieving a  $\geq 4$ -fold rise from baseline (before Dose 1). If the baseline measurement is below the LLOQ, a postvaccination assay result  $\geq 4 \times$  LLOQ is considered a seroreponse.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- n = Number of participants with valid and determinate assay results for the specified assay at the given dose/sampling time point.
- Protocol-specified timing for blood sample collection.
- GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times$

LLOQ.

- d. GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (Group 1 [5 through <12 years of age] – Group 2 [16 through 25 years of age]) and the corresponding CI (based on the Student t distribution).
- e. Immunobridging is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67 and the point estimate of the GMR is  $\geq 0.8$ .
- f. SARS-CoV-2 NT50 were determined using the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay. The assay uses a fluorescent reporter virus derived from the USA\_WA1/2020 strain and virus neutralization is read on Vero cell monolayers. The sample NT50 is defined as the reciprocal serum dilution at which 50% of the virus is neutralized.
- g. N = number of participants with valid and determinate assay results both before vaccination and at 1 month after Dose 2. These values are the denominators for the percentage calculations.
- h. n = Number of participants with seroresponse for the given assay at the given dose/sampling time point.
- i. Exact 2-sided CI based on the Clopper and Pearson method.
- j. Difference in proportions, expressed as a percentage (Group 1 [5 through < 12 years of age] – Group 2 [16 through 25 years of age]).
- k. 2-Sided CI, based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.
- l. Immunobridging is declared if the lower bound of the 2-sided 95% CI for the difference in proportions is greater than -10.0%.

Among participants without prior evidence of SARS-CoV-2 infection up to 1 month after Dose 2, 99.2% of children 5 years through <12 years of age and 99.2% of participants 16 through 25 years of age had a seroresponse from before vaccination to 1 month after Dose 2. The difference in proportions of participants who had seroresponse between the 2 age groups (children – young adult) was 0.0% (2-sided 95% CI: -2.0%, 2.2%), meeting the -10% noninferiority criterion (the lower bound of the 2-sided 95% CI for the difference in seroresponse rate  $> -10\%$ ). Results are presented in Table 37.

### Efficacy

An exploratory efficacy analysis (based on a cut-off date of October 8, 2021) in participants 5 to less than 12 years of age without evidence of SARS-CoV-2 infection prior to Dose 2 showed that the observed vaccine efficacy against confirmed COVID-19 occurring at least 7 days after Dose 2 was 90.7% (95% CI: 67.7%, 98.3%), with 3 COVID-19 cases in the vaccine group compared to 16 in the placebo group (2:1 randomization in vaccine group to placebo group).

No severe COVID-19 or multisystem inflammatory syndrome in children (MIS-C) were reported in children 5 to less than 12 years of age, as of the data cut-off date (October 8, 2021).

#### **14.2.4.2 Immunogenicity in Children 5 Years Through <12 Years of Age – After Booster Dose**

Immunogenicity of a booster dose administered 7 to 9 months after the second primary series dose was evaluated in a subset of 67 evaluable study participants with no evidence of prior SARS-CoV-2 infection up to 1 month after the booster dose, and descriptively compared to 96 subjects in the same age group (67 participants randomly selected from the 2-dose analysis set and 29 participants in the 3-dose analysis set) with evaluable immunogenicity data following 2 doses of 10 mcg BNT162b2.

Vaccine effectiveness of a booster dose of COMIRNATY was inferred based on a descriptive analysis of NT50 against the reference strain of SARS-CoV-2 (USA\_WA1/2020). The NT50 GMT at 1 month after the booster dose was increased compared to before the booster dose and after dose 2. See Table 38.

**Table 38: Summary of Geometric Mean Ratios – NT50 – Comparison of 1-Month After Dose 3 With 1-Month After Dose 2 – Participants Without Evidence of Infection – Phase 2/3 – Immunogenicity Set – 5 to <12 Years of Age – Evaluable Immunogenicity Population**

<b>Post-Dose 2 N = 96 GMT (95% CI)</b>	<b>Pre-Booster N = 67 GMT (95% CI)</b>	<b>Post-Booster N = 67 GMT (95% CI)</b>	<b>GMR* Post-Booster/Post- Dose 2 N = 96 GMT (95% CI)</b>
1,253.9 (1,116.0, 1,408.9)	270.1 (229.1, 320.6)	2,720.9 (2,280.1, 3,247.0)	2.17 (1.76, 2.68)

\* GMR and confidence interval based on post-hoc descriptive analysis.

Using a non-validated fluorescence focus reduction neutralization test assay against the Omicron variant of SARS-CoV-2 (B.1.1.529), the NT50 GMT at 1 month after the booster dose among a subset of 17 study participants (614.4 [95% CI: 410.7, 919.2]) was increased compared to the NT50 GMT at 1 month after dose 2 among a subset of 29 study participants (27.6 [95% CI: 22.1, 34.5]).

#### **14.2.5 COMIRNATY (Original: 3 mcg)**

##### **14.2.5.1 Immunogenicity in Children 6 Months Through <5 Years of Age**

###### **14.2.5.1.1 Immunogenicity in Children 6 Months Through <5 Years of Age – After a 3-Dose Primary Series**

Effectiveness in individuals 6 months through <5 years of age is based on a comparison of immune responses in this age group to individuals 16 through 25 years of age.

###### Immunogenicity in Children 2 Through <5 Years of Age

Immunogenicity analyses have been performed in the immunobridging subset of 143 Study 3 participants 2 through <5 years of age without evidence of infection up to 1 month after Dose 3 based on a data cut-off date of April 29, 2022.

SARS-CoV-2 50% neutralizing antibody titers (NT50) were compared between an immunogenicity subset of Phase 2/3 participants 2 through <5 years of age from Study 3 at 1 month after the 3-dose primary course and a randomly selected subset from Study 2 Phase 2/3 participants 16 through 25 years of age at 1 month after the 2-dose primary series, using a microneutralization assay against the reference strain (USA\_WA1/2020). The primary immunobridging analyses compared the geometric mean titers (using a geometric mean ratio [GMR]) and the seroresponse (defined as achieving at least 4-fold rise in SARS-CoV-2 NT50 from before Dose 1) rates in the evaluable immunogenicity population of participants without evidence of prior SARS-CoV-2 infection up to 1 month after Dose 3 in participants 2 through <5 years of age and up to 1 month after Dose 2 in participants 16 through 25 years of age. The prespecified immunobridging criteria were met for both the GMR and the seroresponse difference (Table 39).

**Table 39: SARS-CoV-2 GMTs (NT50) at 1 Month After Vaccination Series and Difference in Percentages of Participants with Seroresponse at 1 Month After Vaccination Series – Immunobridging Subset – Participants 2 Through <5 Years of Age (Study 3) 1 Month after Dose 3 and Participants 16 Through 25 Years of Age (Study 2) 1 Month After Dose 2 – Without Evidence of SARS-CoV-2 Infection – Evaluable Immunogenicity Population**

Geometric Mean Titers (NT50)			
	COMIRNATY <sup>‡</sup>		GMR (95%CI) (2 Through <5 Years of Age/ 16 Through 25 Years of Age) <sup>c,d</sup>
	3 mcg/Dose 2 Through <5 Years of Age (1 Month after Dose 3) n <sup>a</sup> =143	30 mcg/Dose 16 Through 25 Years of Age (1 Month after Dose 2) n <sup>a</sup> =170	
Assay	GMT <sup>b</sup> (95% CI <sup>b</sup> )	GMT <sup>b</sup> (95% CI <sup>b</sup> )	
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>e</sup>	1,535.2 (1,388.2, 1,697.8)	1,180.0 (1,066.6, 1305.4)	1.30 (1.13, 1.50)
Seroresponse Rate			
	COMIRNATY		Difference in Seroresponse Rates % <sup>i</sup> (95% CI <sup>i</sup> ) (2 Through <5 Years of Age minus 16 Through 25 years of age) <sup>k</sup>
	3 mcg/Dose 2 Through <5 Years of Age (1 Month After Dose 3) N <sup>f</sup> =141 n <sup>g</sup> (%) (95% CI <sup>h</sup> )	30 mcg/Dose 16 Through 25 Years of Age (1 Month after Dose 2) N <sup>f</sup> =170 n <sup>g</sup> (%) (95% CI <sup>h</sup> )	
Assay			
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>e</sup>	141 (100.0) (97.4, 100.0)	168 (98.8) (95.8, 99.9)	1.2 (-1.5, 4.2)

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein binding; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Participants who had no serological or virological evidence [(up to 1 month after Dose 2 (Study 2) or 1 month after Dose 3 (Study 3) blood sample collection)] of past SARS-CoV-2 infection [(i.e. N-binding antibody [serum] negative at pre-Dose 1, pre-Dose 3 (Study 3) and 1 month after Dose 2 (Study 2) or 1 month after Dose 3 (Study 3), SARS-CoV-2 not detected by NAAT [nasal swab] at pre-Dose 1, pre-Dose 2, and pre-Dose 3 (Study 3) study visits, and negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 (Study 2) or 1 month after Dose 3 (Study 3) blood collection)] and had no medical history of COVID-19 were included in the analysis.

Note: Seroresponse is defined as achieving a  $\geq 4$ -fold rise from baseline (before Dose 1). If the baseline measurement is below the LLOQ, a postvaccination assay result  $\geq 4 \times$  LLOQ is considered a seroresponse.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- n = Number of participants with valid and determinate assay results for the specified assay at the given dose/sampling time point.
- GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times$  LLOQ.
- GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (2 through <5 years of age minus 16 through 25 years of age) and the corresponding CI (based on the Student t distribution).

- 
- d. Immunobridging is declared if the lower bound of the 2-sided 95% CI for the GMR ratio is greater than 0.67 and the point estimate of the GMR is  $\geq 0.8$ .
  - e. SARS-CoV-2 NT50 were determined using the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay. The assay uses a fluorescent reporter virus derived from the USA\_WA1/2020 strain and virus neutralization is read on Vero cell monolayers. The sample NT50 is defined as the reciprocal serum dilution at which 50% of the virus is neutralized.
  - f. N = number of participants with valid and determinate assay results both before vaccination and at 1 month after Dose 2. These values are the denominators for the percentage calculations.
  - g. n = Number of participants with seroresponse for the given assay at the given dose/sampling time point.
  - h. Exact 2-sided CI based on the Clopper and Pearson method.
  - i. Difference in proportions, expressed as a percentage (2 through <5 years of age minus 16 through 25 years of age).
  - j. 2-sided CI, based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.
  - k. Immunobridging is declared if the lower bound of the 2-sided 95% CI for the difference in proportions is greater than -10.0% provided that the immunobridging criteria based on GMR were met.

Using a non-validated fluorescence focus reduction neutralization test assay against the Omicron variant of SARS-CoV-2 (BA.1), the NT50 GMT at 1 month after Dose 3 among a subset of 34 study participants without evidence of prior SARS-CoV-2 infection (82.5 [2-sided 95% CI: 55.4, 122.9]) was increased compared to the NT50 GMT before Dose 3 (14.0 [2-sided 95% CI: 10.6, 18.5]).

#### Immunogenicity in Children 6 Months Through <2 Years of Age

Immunogenicity analyses have been performed in the immunobridging subset of 82 Study 3 participants 6 months through <2 years of age without evidence of infection up to 1 month after Dose 3 based on a data cut-off date of 29 April 2022.

SARS-CoV-2 50% neutralizing antibody titers (NT50) 1 month after the vaccination series were compared between an immunogenicity subset of Phase 2/3 participants 6 months through <2 years of age from Study 3 and a randomly selected subset from Study 2 Phase 2/3 participants 16 through 25 years of age, using a microneutralization assay against the reference strain (USA\_WA1/2020). The primary immunobridging analyses compared the geometric mean titers (using a GMR) and the seroresponse (defined as achieving at least 4-fold rise in SARS-CoV-2 NT50 from before Dose 1) rates in the evaluable immunogenicity population of participants without evidence of prior SARS-CoV-2 infection up to 1 month after Dose 3 in participants 6 months through < 2 years of age and up to 1 month after Dose 2 in participants 16 through 25 years of age. The prespecified immunobridging criteria were met for both the GMR and the seroresponse difference (Table 40).



**Table 40: SARS-CoV-2 GMTs (NT50) at 1 Month after Vaccination Series and Difference in Percentages of Participants With Seroreponse at 1 Month After Vaccination Series – Immunobridging Subset – Participants 6 Months Through <2 Years of Age (Study 3) 1 Month After Dose 3 and Participants 16 Through 25 Years of Age (Study 2) 1 Month After Dose 2 – Without Evidence of SARS-CoV-2 Infection– Evaluable Immunogenicity Population**

Geometric Mean Titers (NT50)			
	COMIRNATY <sup>‡</sup>		GMR (95%CI) (6 Months Through <2 Years of Age/ 16 Through 25 Years of Age) <sup>c,d</sup>
	3 mcg/Dose 6 Months Through <2 Years of Age (1 Month After Dose 3) n <sup>a</sup> =82	30 mcg/Dose 16 Through 25 Years of Age (1 Month After Dose 2) n <sup>a</sup> =170	
Assay	GMT <sup>b</sup> (95% CI <sup>b</sup> )	GMT <sup>b</sup> (95% CI <sup>b</sup> )	
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>e</sup>	1,406.5 (1,211.3, 1,633.1)	1,180.0 (1,066.6, 1,305.4)	1.19 (1.00, 1.42)
Seroreponse Rate			
	COMIRNATY		Difference in Seroreponse Rates % <sup>i</sup> (95% CI <sup>i</sup> ) (6 Months Through <2 Years of Age minus 16 Through 25 Years of Age) <sup>k</sup>
	3 mcg/Dose 6 Months Through <2 Years of Age (1 Month After Dose 3) N <sup>f</sup> =80	30 mcg/dose 16 Through 25 Years of Age (1 Month After Dose 2) N <sup>f</sup> =170	
Assay	n <sup>g</sup> (%) (95% CI <sup>h</sup> )	n <sup>g</sup> (%) (95% CI <sup>h</sup> )	
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>e</sup>	80 (100.0) (95.5, 100.0)	168 (98.8) (95.8, 99.9)	1.2 (-3.4, 4.2)

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = nucleoprotein binding; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Participants who had no serological or virological evidence [(up to 1 month after Dose 2 (Study 2) or 1 month after Dose 3 (Study 3) blood sample collection)] of past SARS-CoV-2 infection (i.e. N-binding antibody [serum] negative at pre-Dose 1, pre-Dose 3 (Study 3) and 1 month after Dose 2 (Study 2) or 1 month after Dose 3 (Study 3), SARS-CoV-2 not detected by NAAT [nasal swab] at pre-Dose 1, pre-Dose 2, and pre-Dose 3 (Study 3) study visits, and negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 (Study 2) or 1 month after Dose 3 (Study 3) blood collection)] and had no medical history of COVID-19 were included in the analysis.

Note: Seroreponse is defined as achieving a  $\geq 4$ -fold rise from baseline (before Dose 1). If the baseline measurement is below the LLOQ, a postvaccination assay result  $\geq 4 \times$  LLOQ is considered a seroreponse.

<sup>‡</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. n = Number of participants with valid and determinate assay results for the specified assay at the given dose/sampling time point.

- 
- b. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CI (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times \text{LLOQ}$ .
  - c. GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (6 months through < 2 years of age minus 16 through 25 years of age) and the corresponding CI (based on the Student t distribution).
  - d. Immunobridging is declared if the lower bound of the 2-sided 95% CI for the GMR ratio is greater than 0.67 and the point estimate of the GMR is  $\geq 0.8$ .
  - e. SARS-CoV-2 NT50 were determined using the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay. The assay uses a fluorescent reporter virus derived from the USA\_WA1/2020 strain and virus neutralization is read on Vero cell monolayers. The sample NT50 is defined as the reciprocal serum dilution at which 50% of the virus is neutralized.
  - f. N = number of participants with valid and determinate assay results both before vaccination and at 1 month after Dose 2. These values are the denominators for the percentage calculations.
  - g. n = Number of participants with seroresponse for the given assay at the given dose/sampling time point.
  - h. Exact 2-sided CI based on the Clopper and Pearson method.
  - i. Difference in proportions, expressed as a percentage (6 months through <2 years of age minus 16 through 25 years of age).
  - j. 2-sided CI, based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.
  - k. Immunobridging is declared if the lower bound of the 2-sided 95% CI for the difference in proportions is greater than -10.0% provided that the immunobridging criteria based on GMR were met.

Using a non-validated fluorescence focus reduction neutralization test assay against the Omicron variant of SARS-CoV-2 (BA.1), the NT50 GMT at 1 month after Dose 3 among a subset of 32 study participants without evidence of prior SARS-CoV-2 infection (127.5 [2-sided 95% CI: 90.2, 180.1]) was increased compared to the NT50 GMT before Dose 3 (16.3 [2-sided 95% CI: 12.8, 20.8]).

## 15 MICROBIOLOGY

No microbiological information is required for this product.

## 16 NON-CLINICAL TOXICOLOGY

Non-clinical data reveal no special hazard for humans based on conventional studies of repeat dose toxicity.

### General Toxicology:

In a repeat-dose toxicity study, rats were administered three once weekly doses of 30 mcg/animal (0.06 mL of a vaccine formulation containing the same quantity of nucleoside-modified messenger ribonucleic acid (mRNA) and other ingredients included in a single human dose) of COMIRNATY by intramuscular injection. Vaccine administration resulted in transient erythema and edema at the site of injection, as well as increased cellularity in draining and inguinal lymph nodes, spleen, and bone marrow, along with transiently increased body temperature, increased white blood counts, and decreased reticulocyte counts coupled with decreased red blood cell mass. Clinical chemistry changes (e.g., increased acute phase protein levels) indicated an acute phase response. These changes are consistent with an expected immunostimulatory response following intramuscular administration of a vaccine. Transient periportal hepatocyte vacuolation was also observed without evidence of liver injury. Full or partial recovery from all findings was observed following a 3-week recovery period.

**Carcinogenicity:**

Carcinogenic potential was not assessed, as carcinogenicity studies were not considered relevant to this vaccine.

**Genotoxicity:**

Genotoxic potential was not assessed, as genotoxicity studies were not considered relevant to this vaccine.

**Reproductive and Developmental Toxicology:**

In a reproductive and developmental toxicity study, 30 mcg/animal (0.06 mL of a vaccine formulation containing the same quantity of nucleoside-modified messenger ribonucleic acid (mRNA) and other ingredients included in a single human dose) of COMIRNATY was administered to female rats by the intramuscular route on four occasions: 21 and 14 days prior to mating, and on gestation days 9 and 20. No vaccine-related adverse effects on female fertility, fetal development, or postnatal development were reported in the study.

## PATIENT MEDICATION INFORMATION

### READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

#### COMIRNATY®

#### COVID-19 mRNA Vaccine, Suspension for Intramuscular Injection

This leaflet is a summary and will not tell you everything about this vaccine. Talk to your/your child's healthcare professional about your/your child's medical condition and treatment and ask if there is any new information about **COMIRNATY**.

#### What is COMIRNATY used for?

COMIRNATY is a vaccine used to provide protection against COVID-19 disease caused by the SARS-CoV-2 virus.

COMIRNATY can be given to people 6 months of age and older.

The safety and effectiveness of COMIRNATY for individuals 6 months of age and older are based on studies which evaluated the primary series and booster vaccination with COMIRNATY (Original) and supported by studies which evaluated a booster dose of COMIRNATY Original & Omicron BA.4/BA.5 in individuals 6 months of age and older. Data obtained with COMIRNATY (Original) and COMIRNATY Original & Omicron BA.4/BA.5 are relevant to subsequent variant updated COMIRNATY vaccines because these vaccines are manufactured using the same process.

#### How does COMIRNATY work?

The vaccine causes our body to produce protection (such as antibodies) that prevent the COVID-19 virus from entering our cells to make us sick. The vaccine uses a new method (messenger RNA - mRNA, the genetic code for a piece of the virus) to help our bodies make protection against the virus. The vaccine is given by injection with a needle in the upper arm.

You cannot get COVID-19 from the vaccine.

As with any vaccine, COMIRNATY may not fully protect all those who receive it. Even after you/your child have had the vaccine, continue to follow the recommendations of local public health officials to prevent spread of COVID-19.

#### What are the ingredients in COMIRNATY?

Medicinal ingredient: mRNA encoding SARS-CoV-2 spike protein

The mRNA encoding spike protein is derived from Omicron variant KP.2.

Non-medicinal ingredients:

- ALC-0315 = ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
- ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
- cholesterol
- DSPC = 1,2-distearoyl-sn-glycero-3-phosphocholine
- sodium chloride\*
- sucrose
- tromethamine

- tromethamine hydrochloride
- water for injection

\* present only in the vial with yellow cap/label border (for age 6 months through 4 years) following dilution with 0.9% Sodium Chloride Injection USP.

**COMIRNATY comes in the following dosage forms:**

Suspension for intramuscular injection, provided as follows (not all presentations may be available):

For 12 Years of Age and Older:

- **Single Dose Vial with Light Gray Cap and Light Gray Label Border (DO NOT DILUTE):** 1 dose of 0.3 mL (30 micrograms mRNA/0.3 mL).
- **Multiple Dose Vial with Dark Gray Cap and Dark Gray Label Border (DO NOT DILUTE):** 6 doses of 0.3 mL (30 micrograms mRNA/0.3 mL).
- **Single Dose Prefilled Syringe:** 1 dose of 0.3 mL (30 micrograms mRNA/0.3 mL).

For Age 5 Years Through 11 Years:

- **Single Dose Vial with Light Blue Cap and Light Blue Label Border (DO NOT DILUTE):** 1 dose of 0.3 mL (10 micrograms mRNA/0.3 mL).
- **Multiple Dose Vial with Dark Blue Cap and Dark Blue Label Border (DO NOT DILUTE):** 6 doses of 0.3 mL (10 micrograms mRNA/0.3 mL).

For Age 6 Months Through 4 Years:

- **Multiple Dose Vial with Yellow Cap and Yellow Label Border (DILUTE PRIOR TO USE):** 3 doses of 0.3 mL after dilution (3 micrograms mRNA/0.3 mL).

**You/your child should not receive COMIRNATY if:**

- you/your child are allergic to any of the ingredients in this vaccine (see **What are the ingredients in COMIRNATY?**).
- you/your child had a severe allergic reaction after a previous dose of any COMIRNATY vaccine.
- you/your child have any symptoms that could be due to COVID-19. Talk with your/your child's healthcare professional about your/your child's symptoms and getting a COVID-19 test. Your/your child's healthcare professional will advise you when you/your child are able to receive the vaccine.

**To help avoid side effects and ensure proper use, talk to your/your child's healthcare professional before you/your child receive COMIRNATY. Talk about any health conditions or problems you/your child may have, including if you/your child:**

- have had any problems following a previous dose of any COMIRNATY vaccine, such as an allergic reaction or breathing problems
- have any allergies
- have a weakened immune system due to a medical condition or are on a medicine that affects the immune system
- have previously had episodes of myocarditis (inflammation of the heart muscle) and/or pericarditis (inflammation of the outer lining of the heart)

- are feeling nervous about the vaccination process or have ever fainted in association with an injection
- have a bleeding problem, bruise easily or use a blood thinning medication
- are pregnant, think you may be pregnant or plan to become pregnant
- are breast-feeding

**Other warnings you should know about:**

As with any vaccine, COMIRNATY may not fully protect all those who receive it.

Some of the effects of vaccination mentioned under “***What are possible side effects from using COMIRNATY?***” may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.

**Tell your/your child’s healthcare professional about all the medicines you/your child take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

COMIRNATY may be given at the same time as a flu vaccine in adults 18 through 64 years of age.

Tell your healthcare professional if you/your child have recently received any other vaccine.

**How COMIRNATY is given:**

**Usual dose:**

For 12 Years of Age and Older

COMIRNATY is given as an injection of 0.3 mL, preferably into a muscle of the upper arm.

You will receive 1 injection, regardless whether you have received a COVID-19 vaccine before.

If you were previously vaccinated with a COVID-19 vaccine, you should not receive a dose of COMIRNATY until at least 3 to 6 months after the most recent dose.

For Age 5 Years Through 11 Years

COMIRNATY is given as an injection of 0.3 mL, preferably into a muscle of the upper arm.

Your child will receive 1 injection, regardless whether he/she has received a COVID-19 vaccine before.

If your child was previously vaccinated with a COVID-19 vaccine, he/she should not receive a dose of COMIRNATY until at least 6 months after the most recent dose.

For Age 6 Months Through 4 Years

COMIRNATY is given as an injection of 0.3 mL, into a muscle of the thigh in infants from 6 to less than 12 months of age. In infants and children 1 year of age or older, it is given as an injection of 0.3 mL into a muscle of the thigh or into a muscle of the upper arm.

If your child has not completed a COVID-19 primary vaccination course, your child will receive a maximum of 3 injections (the total number of doses required as primary course). It is recommended to receive the second dose 3 weeks after the first dose followed by a third dose at least 8 weeks after the second dose to complete the three-dose course. If your child has started a three-dose course with COMIRNATY Omicron XBB.1.5, they may complete the three-dose course with COMIRNATY.

If your child has previously completed a COVID-19 primary vaccination course, your child will receive 1 injection. If your child was previously vaccinated with a COVID-19 vaccine, your child should not receive a dose of COMIRNATY until at least 6 months after the most recent dose.

If you have any further questions on the use of COMIRNATY, ask your healthcare professional.

#### **Overdose:**

In the event of suspected overdose with COMIRNATY, contact your regional poison control centre.

#### **Missed Dose:**

If you forget to go back to your healthcare professional at the scheduled time for your/your child's next dose, ask your/your child's healthcare professional for advice.

#### **What are possible side effects from using COMIRNATY?**

Like all vaccines, COMIRNATY can cause side effects, although not everybody gets them.

Side effects may occur at the following frequencies:

**Very common:** may affect more than 1 in 10 people

- irritability (6 months to <2 years)
- injection site pain/tenderness, swelling
- tiredness
- headache
- muscle pain
- chills
- joint pain
- fever
- diarrhea

**Common:** may affect more than 1 in 100 and up to 1 in 10 people

- injection site redness ("very common" in 6 months to <12 years)
- nausea
- vomiting
- rash (6 months to <2 years)
- enlarged lymph nodes (more frequently observed after the booster dose)

**Uncommon:** may affect more than 1 in 1000 and up to 1 in 100 people

- feeling unwell
- arm pain
- feeling weak or lack of energy/sleepy
- decreased appetite ("very common" for 6 months to <2 years)
- excessive sweating
- night sweats

Non-severe allergic reactions (such as rash, itching, hives or swelling of the face), severe allergic reactions, facial paralysis / Bell's palsy, erythema multiforme (skin reaction or lesion; red spots or patches), hypoesthesia (reduced or loss of sensation) and paresthesia ("tingling sensation") have been reported.

Myocarditis (inflammation of the heart muscle) and/or pericarditis (inflammation of the outer lining of the heart) have been reported following COMIRNATY administration. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as shortness of breath, palpitations and chest pain, and seek immediate medical attention should these occur. These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often in younger males, and more often after the second dose or first booster dose compared to the first dose. Most cases of myocarditis and pericarditis recover. Some cases required intensive care support and fatal cases have been seen.

These are not all the possible side effects you/your child may have when receiving COMIRNATY. If you/your child experience any side effects not listed here, tell your/your child's healthcare professional.

There is a remote chance that COMIRNATY could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of COMIRNATY. For this reason, the vaccination provider may ask you/your child to stay at the place where the vaccine was received for monitoring after vaccination. Should you/your child develop any serious symptoms or symptoms that could be an allergic reaction, seek medical attention right away. Symptoms of an allergic reaction include:

- hives (bumps on the skin that are often very itchy)
- swelling of the face, tongue or throat
- difficulty breathing
- a fast heartbeat
- dizziness and weakness

If you/your child experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Your/your child's health care provider should inform your local public health department of any serious side effects after vaccination.

#### **Reporting Suspected Side Effects for Vaccines**

**For the general public:** Should you experience a side effect following immunization, please report it to your healthcare professional.

Should you require information related to the management of the side effect, please contact your healthcare professional. The Public Health Agency of Canada, Health Canada and Pfizer Canada ULC cannot provide medical advice.

**For healthcare professionals:** If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (<https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/form.html>) and send it to your local Health Unit.



**Storage:**

COMIRNATY should be stored, supplied and administered by a healthcare professional.

Keep out of reach and sight of children.

**If you want more information about COMIRNATY:**

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website [www.pfizer.ca], or by calling 1-800-463-6001 (Pfizer Medical Information).

This leaflet was prepared by Pfizer Canada ULC.

Last Revised: October 25, 2024